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A B S T R A C T
Background
Inflammatory bowel disease (IBD), comprised of Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic mucosal
inflammation, frequent hospitalizations, adverse health economics, and compromised quality of life. Diet has been hypothesised to
influence IBD activity.
Objectives
To evaluate the efficacy and safety of dietary interventions on IBD outcomes.
Search methods
We searched the Cochrane IBD Group Specialized Register, CENTRAL, MEDLINE, Embase, Web of Science, Clinicaltrials.gov
and the WHO ICTRP from inception to 31 January 2019. We also scanned reference lists of included studies, relevant reviews and
guidelines.
Selection criteria
We included randomized controlled trials (RCTs) that compared the effects of dietary manipulations to other diets in participants with
IBD. Studies that exclusively focused on enteral nutrition, oral nutrient supplementation, medical foods, probiotics, and parenteral
nutrition were excluded.
Data collection and analysis
Two review authors independently performed study selection, extracted data and assessed bias using the risk of bias tool. We conducted
meta-analyses where possible using a random-effects model and calculated the risk ratio (RR) and corresponding 95% confidence
interval (CI) for dichotomous outcomes. We assessed the certainty of evidence using GRADE.
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Main results
The review included 18 RCTs with 1878 participants. The studies assessed different dietary interventions for active CD (six studies),
inactiveCD(seven studies), activeUC (one study) and inactiveUC (four studies).Dietary interventions involved either the consumption
of low amounts or complete exclusion of one or more food groups known to trigger IBD symptoms. There was limited scope for data
pooling as the interventions and control diets were diverse. The studies were mostly inadequately powered. Fourteen studies were rated
as high risk of bias. The other studies were rated as unclear risk of bias.
The effect of high fiber, low refined carbohydrates, lowmicroparticle diet, low calcium diet, symptoms-guided diet and highly restricted
organic diet on clinical remission in active CD is uncertain. At 4 weeks, remission was induced in: 100% (4/4) of participants in the
low refined carbohydrates diet group compared to 0% (0/3) of participants in the control group (RR 7.20, 95% CI 0.53 to 97.83; 7
participants; 1 study; very low certainty evidence). At 16 weeks, 44% (23/52) of participants in the low microparticle diet achieved
clinical remission compared to 25% (13/51) of control-group participants (RR 3.13, 95%CI 0.22 to 43.84; 103 participants; 2 studies;
I² = 73%; very low certainty evidence). Fifty per cent (16/32) of participants in the symptoms-guided diet group achieved clinical
remission compared to 0% (0/19) of control group participants (RR 20.00, 95% CI 1.27 to 315.40; 51 participants ; 1 study; very low
certainty evidence) (follow-up unclear). At 24 weeks, 50% (4/8) of participants in the highly restricted organic diet achieved clinical
remission compared to 50% (5/10) of participants in the control group (RR 1.00, 95% CI 0.39 to 2.53; 18 participants; 1 study; very
low certainty evidence). At 16 weeks, 37% (16/43) participants following a low calcium diet achieved clinical remission compared to
30% (12/40) in the control group (RR 1.24, 95% CI 0.67 to 2.29; 83 participants; 1 study; very low certainty evidence).
The effect of low refined carbohydrate diets, symptoms-guided diets and low red processed meat diets on relapse in inactive CD is
uncertain. At 12 to 24 months, 67% (176/264) of participants in low refined carbohydrate diet relapsed compared to 64% (193/303)
in the control group (RR 1.04, 95% CI 0.87 to 1.25; 567 participants; 3 studies; I² = 35%; low certainty evidence). At 6 to 24 months,
48% (24/50) of participants in the symptoms-guided diet group relapsed compared to 83% (40/48) participants in the control diet (RR
0.53, 95% CI 0.28 to 1.01; 98 participants ; 2 studies; I² = 54%; low certainty evidence). At 48 weeks, 66% (63/96) of participants in
the low red and processed meat diet group relapsed compared to 63% (75/118) of the control group (RR 1.03, 95% CI 0.85 to 1.26;
214 participants; 1 study; low certainty evidence). At 12 months, 0% (0/16) of participants on an exclusion diet comprised of low
disaccharides / grains / saturated fats / red and processed meat experienced clinical relapse compared to 26% (10/38) of participants
on a control group (RR 0.11, 95% CI 0.01 to 1.76; 54 participants; 1 study; very low certainty evidence).
The effect of a symptoms-guided diet on clinical remission in active UC is uncertain. At six weeks, 36% (4/11) of symptoms-guided diet
participants achieved remission compared to 0% (0/10) of usual diet participants (RR 8.25, 95% CI 0.50 to 136.33; 21 participants;
1 study; very low certainty evidence).
The effect of the Alberta-based anti-inflammatory diet, the Carrageenan-free diet or milk-free diet on relapse rates in inactive UC is
uncertain. At 6 months, 36% (5/14) of participants in the Alberta-based anti-inflammatory diet group relapsed compared to 29% (4/
14) of participants in the control group (RR 1.25, 95% CI 0.42 to 3.70; 28 participants; 1 study; very low certainty evidence). Thirty
per cent (3/10) of participants following the carrageenan-free diet for 12 months relapsed compared to 60% (3/5) of the participants
in the control group (RR 0.50, 95% CI 0.15 to 1.64; 15 participants; 1 study; very low certainty evidence). At 12 months, 59% (23/
39) of milk free diet participants relapsed compared to 68% (26/38) of control diet participants (RR 0.83, 95% CI 0.60 to 1.15; 77
participants; 2 studies; I² = 0%; low certainty evidence).
None of the included studies reported on diet-related adverse events.
Authors’ conclusions
The effects of dietary interventions on CD and UC are uncertain. Thus no firm conclusions regarding the benefits and harms of dietary
interventions in CD and UC can be drawn. There is need for consensus on the composition of dietary interventions in IBD and
more RCTs are required to evaluate these interventions. Currently, there are at least five ongoing studies (estimated enrollment of 498
participants). This review will be updated when the results of these studies are available.
P L A I N L A N G U A G E S U M M A R Y
Diets for inducing and maintaining remission in inflammatory bowel disease (IBD)
What is the aim of the review?
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The aim was to find out what diets can be used to induce or maintain remission in people with IBD.
What is IBD?
IBD involves inflammation of the gastrointestinal tract. Ulcerative colitis (UC) and Crohn’s disease (CD) are themost common types of
IBD. Symptoms include abdominal pain, diarrhea and rectal bleeding. IBD is characterized by periods of relapse where people experience
symptoms of active disease and periods of remission when the symptoms stop. While some foods may provoke IBD symptoms, little
is known about whether diets help to induce or maintain remission in IBD.
How up to date is the review?
We searched for studies up to 31 January 2019.
What are the main results of the review?
We found 18 studies including 1878 participants. The diets studied included reduction or exclusion of foods believed to provoke IBD
symptoms. These diets were compared with ’usual’ diets. The studies assessed dietary interventions for active CD (six studies), inactive
CD (seven studies), active UC (one study) and inactive UC (four studies). One study recruited children, while the rest included adults.
The studies were poorly designed and had few participants. As a result the overall quality of the evidence was very low.
The effect of high fiber, low refined carbohydrates, low microparticle, low calcium, symptoms-guided diet and highly restricted organic
diet on clinical remission in active CD is uncertain. In one study, remission was achieved at 4 weeks in 100% (4/4) of low refined
carbohydrates participants compared to 0% (0/3) of usual diet participants. In a pooled analysis of two studies, 44% (23/52) of low
microparticle participants achieved remission at 16 weeks compared to 25% (13/51) of usual diet participants. One study found that
50% (16/32) of symptoms-guided participants achieved remission compared to 0% (0/19) of usual diet participants. One study found
that 50% (4/8) of highly-restricted organic diet participants achieved remission at 24 weeks compared to 50% (5/10) of usual diet
participants. One study found that 37% (16/43) of low-calcium participants achieved remission at 16 weeks compared to 30% (12/
40) of usual diet participants.
The effect of low refined carbohydrate, symptoms-guided and low red processed meat diets on relapse in inactive CD is uncertain. In
a pooled analysis of three studies, 67% (176/264) of low refined carbohydrate participants relapsed at 12 to 24 months compared to
64% (193/303) of usual diet participants. In a pooled analysis of two studies, 48% (24/50) of symptoms-guided participants relapsed
at 6 to 24 months compared to 83% (40/48) of usual diet participants. One study found that 66% (63/96) of low red and processed
meat participants relapsed at 48 weeks compared to 63% (75/118) of usual diet participants. One study showed that 0% (0/16) of
exclusion diet participants (i.e. low disaccharides, grains, saturated fats, red and processed meat) relapsed at 12 months compared to
26% (10/38) of usual diet participants.
The effect of a symptoms-guided diet on clinical remission in active UC is uncertain. In one study, 36% (4/11) of symptoms-guided
participants achieved remission at six weeks compared to 0% (0/10) in the usual diet group.
The effect of the Alberta-based anti-inflammatory diet, the Carrageenan-free diet and the milk-free diet on relapse in inactive UC is
uncertain. In one study, 36% (5/14) of Alberta-based diet participants relapsed at 6 months compared to 29% (4/14) of usual diet
participants. In one study, 30% (3/10) of carrageenan-free participants relapsed at 12 months compared to 60% (3/5) of usual diet
participants. At 12 months, 59% (23/39) of milk-free diet participants relapsed compared to 68% (26/38) in the usual diet group.
None of the included studies reported on diet-related side effects.
Conclusions
The effects of dietary interventions on CD and UC are uncertain. Thus no firm conclusions regarding the benefits and harms of dietary
interventions in CD and UC can be drawn. There is need for consensus on the composition of dietary interventions in IBD and more
studies are required to evaluate these interventions. Currently, there are five ongoing studies (estimated enrollment of 498 participants).
This review will be updated when the results of these studies are available.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intervention diet compared to control diet in active Crohn’s disease for induction of remission in active Crohn’s disease
Patient or population: people with act ive Crohn’s disease
Setting: home
Intervention: intervent ion diet (various)
Comparison: control diet (various)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with control diet Risk with intervention
diet
Induct ion of remission
at 4 weeks - High-
f iber, low ref ined carbo-
hydrates diet
Study populat ion RR 7.20
(0.53 to 97.83)
7 (1 study) ⊕©©©
VERY LOW1,2
We were unable to cal-
culate absolute ef fects.
Remission was induced
in 100% (4/ 4) of par-
t icipants in the low
ref ined carbohydrates
diet group compared to
0% (0/ 3) in the control
group
Clinical remission was
def ined as CDAI ≤150
0 per 1,000 0 per 1,000
(0 to 0)
Induct ion of remission
at 16 weeks - Low mi-
cropart icle diet
Study populat ion RR 3.13
(0.22 to 43.84)
103 (2 studies) ⊕©©©
VERY LOW1,3
Clinical remission was
def ined as CDAI ≤150
255 per 1,000 798 per 1,000
(56 to 1,000)
Induct ion of remission
at 16 weeks - Low cal-
cium diet
Study populat ion RR 1.24
(0.67 to 2.29)
83 (1 study) ⊕©©©
VERY LOW1,4
Clinical remission was
def ined as CDAI ≤150
300 per 1000 372 per 1000 (201 to
687)
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Induct ion of remis-
sion (t imef rame not re-
ported) - Symptoms-
guided diet
Study populat ion RR 20.00
(1.27 to 315.40)
51 (1 study) ⊕©©©
VERY LOW1,5
We were unable to cal-
culate absolute ef fects.
Remission was induced
in 50% (16/ 32) of par-
t icipants in the symp-
toms-guided diet group
compared to 0% (0/ 19)
in the control
Clinical remission was
def ined as CDAI ≤150
0 per 1,000 0 per 1,000
(0 to 0)
Induct ion of remission
at 6 weeks - Highly re-
stricted, organic diet
Study populat ion RR 1.00
(0.39 to 2.53)
18 (1 study) ⊕©©©
VERY LOW1,6
Clinical remission was
def ined as CDAI ≤150
500 per 1,000 500 per 1,000
(195 to 1,000)
Health-related quality
of lif e (t imef rame not
reported) - IBDQ -Symp-
toms-guided diet
The mean health re-
lated quality of lif e -
IBDQ - was 0
MD 23.75 higher
(7.12 higher to 40.38
higher)
- 51 (1 study) ⊕⊕©©
LOW1,7
Health-related quality
of lif e at 6 weeks - IBDQ
- Highly restricted, or-
ganic diet
The mean health re-
lated quality of lif e -
IBDQ was 0
MD 4 higher
(17.86 lower to 25.86
higher)
- 14 (1 study) ⊕©©©
VERY LOW1,8
Adverse events None reported in any of the studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: risk rat io; CDAI: Crohn’s disease act ivity index; IBDQ: Inf lammatory Bowel Disease Quest ionnaire; MD: Mean dif ference.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
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Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high or unclear risk of bias
2 Downgraded two levels due to serious imprecision (4 events)
3 Downgraded two levels due to serious imprecision (36 events)
4 Downgraded two levels due to serious imprecision (28 events)
5 Downgraded two levels due to serious imprecision (16 events)
6 Downgraded two levels due to serious imprecision (9 events)
7 Downgraded one level due to imprecision (51 part icipants)
8 Downgraded two levels due to serious imprecision (14 part icipants)
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B A C K G R O U N D
Description of the condition
Inflammatory bowel disease (IBD), predominantly comprised of
Crohn’s disease (CD) and ulcerative colitis (UC), is characterized
by chronic mucosal inflammation, frequent hospitalizations, ad-
verse health economics, and compromised quality of life. Com-
mon symptoms of IBD include abdominal pain, diarrhoea, and
rectal bleeding. Inflammation in UC is limited to the colonic mu-
cosa. Inflammation in CD is a non-uniform transmural disease
process that can occur anywhere along the alimentary tract and
can lead to complications including intestinal strictures, fistuliza-
tion to surrounding tissues or organs, and abscesses. Other com-
plications that can arise in both CD and UC include intestinal
cancer, nutrient malabsorption, malnutrition, and extra-intestinal
manifestations (e.g. arthralgias, dermatologic lesions, uveitis).
The incidence of CD is approximately 20 per 100,000 person-
years in North America and 13 per 100,000 person-years in Eu-
rope (Molodecky 2012). Higher disease incidence and prevalence
are seen in North America and Europe compared to lower rates in
Asia and the Middle East. Nonetheless, the incidence and preva-
lence of IBD have more recently been rising in Asia and the Mid-
dle East, and individuals from these geographic regions experience
an increased risk of developing IBD when immigrating to North
America or Europe (Benchimol 2015; Pinsk 2007). This overall
increase in IBD among populations not traditionally associated
with IBD has been hypothesized to stem from the Westernization
of lifestyles and diets (Foster 2013; Ooi 2016). For example, im-
migrants from Latin American to South Florida develop IBD at
a later age; however, first-generation US-born Hispanics develop
IBD at an age similar to non-Hispanic whites (Damas 2013). The
development of IBD in this generation of immigrants is also oc-
curring sooner than previously documented (Damas 2017).
Factors that contribute to the development of IBD are unclear,
although the current paradigm of pathogenesis involves the in-
teraction of disease-susceptibility genes, inappropriate immune
response, gut microbiota, and environmental factors (Abraham
2009). Somepotential environmental factors include gastrointesti-
nal infections, antibiotics, tobacco use, and oral contraceptives
(Birrenbach 2004; Cornish 2008; Garcia Rodriguez 2006; Gradel
2009; Ungaro 2014). Epidemiologic studies have implicated diet
in IBD pathogenesis (Chapman-Kiddell 2010). Increased intake
of refined sugars has been associated with an increased risk of
CD in several small cohort studies (Bianchi 1985; Hansen 2011;
Jakobsen 2013; Martini 1976; Silkoff 1980). Other studies have
associated dietary fiber consumption with a reduced risk of CD
(Amre 2007; Persson 1992; Thornton 1979). An analysis of the
Nurses’ Health Study that included 170,776 adult women, who
were prospectively followed over 26 years, revealed that long-term
consumption of dietary fiber was associated with a reduced inci-
dence of CD (Ananthakrishnan 2013). Compared with the lowest
quintile of energy-adjusted cumulative average intake of dietary
fiber, intake of the highest quintile (median of 24.3 g/day of di-
etary fiber) was associated with a 40% reduction in risk of CD.
Fiber derived from fruits was significantly associated with a re-
duced risk of CD, while fiber from vegetables, cereals, and whole
grains was not associated with a reduced risk of IBD. A separate
analysis of the Nurses’ Health Study revealed that higher intakes
of fruits, vegetables, and fish in high school were associated with
a 53% lower risk of developing CD with fish having the greatest
impact (Ananthakrishnan 2015). Dietary fat may also play a role
in CD pathogenesis, although this relationship appears less clear.
Some studies have associated an increased fat intake with CD risk
(Hou 2011; Reif 1997; Sakamoto 2005). However, an analysis of
the large prospective Nurses’ Health Study did not find an asso-
ciation between the intake of total fat, saturated fats, unsaturated
fats, omega-6 polyunsaturated fatty acids (PUFAs), or omega-3
PUFAs and CD risk (Ananthakrishnan 2014). A greater intake
of omega-3 PUFAs and higher ratio of n-3:n-6 PUFAs were as-
sociated with a lower risk of UC. Furthermore, high long-term
intake of trans-unsaturated fatty acids was associated with a trend
towards an increased incidence of UC. Table 1 summarizes the
influence of some dietary components on the risk of IBD.
Given its potential effects on disease pathogenesis, dietary intake
has similarly been hypothesized to influence disease activity. For
instance, exclusive enteral nutrition may be effective for the in-
duction and maintenance of remission in pediatric CD (Akobeng
2018; Critch 2012; Narula 2018). A high intake of red and pro-
cessed meat or alcoholic beverages may increase the risk of a UC
flare among adults (Jowett 2004). Diet-derived micronutrients,
such as zinc, iron, and vitamin D, may have modifying effects on
immunity, barrier function, and oxidative load with a downstream
potential to impact the course of CD (Brown 2011; Lih-Brody
1996; Limketkai 2016). There may be a role of nutritional thera-
pies for the induction and maintenance of remission in IBD, al-
though the potential efficacy may vary according to diet compo-
sition, disease type, and age group (pediatric or adult).
Description of the intervention
The intervention is a controlled manipulation of the subject’s oral
diet by a deliberate change in the consumption of food (i.e. no
formulas or supplements used) for a specified period of time.
How the intervention might work
Themechanisms that drive the benefits or harms of diets in IBDare
unclear, although studies on dietary macronutrients may provide
some insight. For instance, omega-6 PUFAs are pro-inflammatory
mediators, while omega-3 PUFAs, medium-chain oils, and a fam-
ily of diverse plant-derived flavonoids (e.g. phytonutrients) have
anti-inflammatory properties (Kono 2010; Papada 2014). Dietary
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fiber can be converted by intestinal bacteria to short-chain fatty
acids, which have anti-inflammatory properties (Galvez 2005). In
IBD mouse models, high-fat diets promote further intestinal in-
flammation by disrupting gut barrier function and the resident
microbiome (Devkota 2012; Gruber 2013; van der Logt 2013).
Similarly, one of the theories underlying the efficacy of exclusive
enteral nutrition or elimination diets for induction of remission in
IBD relates to an avoidance of dietary triggers. These pro- or anti-
inflammatory nutrients are thus suspected to confer respective pro-
or anti-inflammatory properties of diets. Others have hypothe-
sized that people with IBD may possess individualized food sen-
sitivities and disease activity could improve with the personalized
exclusion of foods that provoke symptoms or cause abnormal in-
creases in food-specific IgG antibodies (Bentz 2010; Gunasekeera
2016; Rajendran 2011), although food-specific IgG antibodies
have not been found to correlate with gastrointestinal symptom
severity (Zuo 2007). The elimination of foods that are high in
short-chain carbohydrates (i.e. FODMAP: Fermentable Oligo-
, Di-, Monosaccharides, And Polyols) may improve CD symp-
toms through several possible mechanisms including reduction
of gaseous byproducts of bacterial fermentation, gaseous disten-
tion, osmotic diarrhoea, and shifts in the gut microbiome (Gearry
2009; Gibson 2015; Halmos 2015; Halmos 2016; Prince 2016;
See Figure 1).
Figure 1. Source: Mullin 2016.
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Why it is important to do this review
Patients and clinicians have long sought guidance on the dietary
management of IBD. A prospective evaluation of 400 consecutive
IBD patients at a tertiary-care center reported that approximately
half felt that diet could be the initiating factor in their disease
and the majority cited food provocation of IBD symptoms (57%)
and disease flares (60%) (Limdi 2016). Several ’brand’ diets (e.g.
Specific Carbohydrate Diet, gluten-free diet, Anti-Inflammatory
Diet, Gut and Psychology Diet) are promoted on the internet by
healthcare practitioners and even non-licensed individuals, often
without supporting evidence. These diet programs restrict, ex-
clude, or promote the intake of differing food types to achieve
purported improvements in IBD symptoms. Several clinical trials
and observational cohort studies have studied the effects of diverse
diets on clinical endpoints in IBD. Nonetheless, the individual
studies are often limited by small sample sizes, suboptimal study
design, and inconsistent findings. Despite several opinion papers
and reviews on the issue of dietary management of IBD, there is
still no consensus or clear guidance in the literature on optimal di-
etary therapies for induction or maintenance of remission in IBD.
A systematic review is lacking and could potentially benefit both
clinicians and patients to guide dietary management of IBD based
on the best available evidence.
O B J E C T I V E S
The objective of this systematic review is to evaluate the efficacy
and safety of dietary interventions on IBD outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) were considered for inclu-
sion.
Types of participants
Adults or children with established IBD (CD, UC) were consid-
ered for inclusion. For studies that only reported on IBD, we con-
tacted the authors to request a breakdown of results for partici-
pants withCDandUC.Trials conducted in all settings (e.g. single-
center, multi-center) with any establishedmethod used to confirm
disease diagnosis were included. Studies were not included unless
stratified results for IBD (CD and UC) were provided.
Types of interventions
Interventions of interest included all defined oral diets compared
to a different or unrestricted oral diet. Studies that exclusively fo-
cused on enteral nutrition, oral nutrient supplementation, medi-
cal foods, probiotics, and parenteral nutrition were excluded.
Types of outcome measures
Primary outcomes
Primary outcomes were induction and maintenance of remission
as defined by the included studies.
1. Induction of remission involves the therapeutic reduction
of intestinal symptoms below a clinical threshold as measured by
CD and UC symptom scores, including the Pediatric Crohn’s
Disease Activity Index (PCDAI), the Crohn’s Disease Activity
Index (CDAI), the Harvey-Bradshaw Index (HBI), the Mayo
score, modified Mayo score or Colitis Activity Index (CAI).
2. Maintenance of remission involves the continual abatement
of symptoms over time attributable to a therapeutic modality (in
this case, diet). Maintenance of remission will be assessed based
on available fixed time intervals (e.g. six months, one year) and as
variable time contributions (e.g. person-years). A clinical relapse
is defined as the transition from a state of clinical remission to
active disease, based on symptom scores (i.e. PCDAI, CDAI,
HBI, Mayo score, or CAI).
Although symptom scores are validated indices routinely used to
assess disease activity in IBD clinical trials, a potential limitation
is the inability to differentiate between IBD or irritable bowel syn-
drome (IBS)-associated mediators of non-specific gastrointestinal
symptoms.
Secondary outcomes
Secondary outcomes (when available) were the following:
1. Clinical improvement as defined by the included studies;
2. Corticosteroid-free remission;
3. Surrogate biomarkers of inflammation (i.e., erythrocyte
sedimentation rate [ESR] and C-reactive protein [CRP]), fecal
biomarkers (i.e., calprotectin);
4. Endoscopic endpoints of improvement and remission;
5. Histologic endpoints of improvement and remission;
6. Health-related quality of life as measured by the
Inflammatory Bowel Disease Questionnaire (IBDQ), Short
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Inflammatory Bowel Disease Questionnaire (SIBDQ), or related
surveys;
7. Hospitalizations;
8. Need for surgery;
9. Progression of disease from a state of inflammation-only
disease to stricturing/obstructing to penetrating/fistulizing
disease;
10. Escalation of therapy including the need to add or modify
pharmacologic therapy due to lack of efficacy at inducing or
maintaining remission after enrollment in the trial;
11. Adverse events;
12. Withdrawal due to adverse events; and
13. Serious adverse events.
Search methods for identification of studies
Electronic searches
We conducted a comprehensive and systematic search to identify
RCTs and non-randomized studies (i.e. cohort or case-control)
from inception to 31 January 2019 using the following databases:
• CENTRAL;
• Cochrane IBD Group Specialized Trials Register;
• Embase (Ovid);
• MEDLINE (Ovid); and
• Web of Science.
We searched databases using controlled vocabulary and keywords
(details in appendices). No restrictions were placed on publica-
tion dates (after 1966) or language. Note that the searches were
designed to include interventional and observational studies on
adults and children but exclude those using oral nutrition supple-
ments (enteral nutrition drinks, tube feeds), medical foods, pro-
biotics, parenteral nutrition or a combination of these modalities.
We report the detailed search strategies in Appendix 1.
Searching other resources
We searched reference lists from included articles and any exist-
ing relevant reviews. We also scanned proceedings from Digestive
Disease Week (2005 to date), Advances in Inflammatory Bowel
Disease (2005 to date), Clinical Nutrition Week (2005 to date),
European Crohn’s and Colitis Organisation (2005 to date), and
United European Gastroenterology Week (2005 to date). We also
searched ongoing trials registered in ClinicalTrials.gov and the
WHO International Clinical Trials Registry Platform portal.
Data collection and analysis
This review has been carried out according to methods presented
in the published protocol (Limketkai 2017), which are based on
the Cochrane Handbook (Higgins 2011).
Selection of studies
The stages of article selection included the following: (i) title
screening; (ii) abstract screening; and (iii) full-text review. Two au-
thors (BNLandGEM) independently reviewed each article at each
stage of selection. Included and excluded studies were recorded.
1. Title screening involved selection of articles that reported
studies with even a minor possibility of inclusion. Articles that
are clearly unrelated were excluded. Adjudication did not occur
at the title screening stage and ambiguous studies were included
by default.
2. Abstract screening involved the selection of articles that
reported studies with a reasonable possibility of inclusion.
Differences in assessment for inclusion were resolved by
discussion between the two independent investigators.
Adjudication did not occur at the abstract screening state and
studies that were ambiguous were included by default.
3. Full-text review involved selection of articles based on
careful examination of the full report. Differences in assessment
for inclusion were resolved by discussion between the two
independent investigators. Adjudication was performed as
needed by a third author (AP).
Data extraction and management
Two authors (TH and ZIE) independently performed data extrac-
tion from each included study. Any discrepancies were resolved
by discussion between the two independent investigators. Adju-
dication was performed as needed by a third author (MG). Ex-
tracted data included the study design, population characteristics,
intervention, comparator, duration of interventions and follow-
up, outcomes, timing, setting, the method of handling missing
data, funding source, and potential conflicts of interest.
Assessment of risk of bias in included studies
Two authors (TH andZIE) independently assessed the study qual-
ity of each included RCT using the Cochrane risk of bias tool. Ad-
judication was performed as needed by a third author (MG). Do-
mains of interest included random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of
outcome assessment, completeness of outcome data, selective re-
porting, and other potential sources of bias (e.g. baseline imbal-
ance). Each domain was assessed as having a low, moderate, high,
or unclear risk of bias. Based on the aggregate assessment of these
items, study quality was rated as good (low risk of bias), fair, or
poor (high or unclear risk of bias). Each domain followed standard
definitions used for Cochrane systematic reviews (Higgins 2011).
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We considered trials which were classified as having a low risk
of bias for sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment,
completeness of outcome data, and selective reporting as low bias-
risk trials. All other trials were considered to be at high risk of bias.
We tabulated the risk of bias in the ’Risk of bias’ table as part of the
’Table of characteristics of included studies’. We also illustrated
the risk of bias of each trial using the ’Risk of bias summary’ and
cross-tabulated all the judgement of risk on a ’Risk of bias graph’.
The overall strength of evidence supporting the primary outcome
and selected secondary outcomes was assessed using the GRADE
(Grades of Recommendation, Assessment, Development, and
Evaluation) criteria (Guyatt 2008; Schünemann 2011). Evidence
from RCTs starts as high quality and evidence from observational
studies starts as low quality. The quality of the evidence can be
downgraded due to risk of bias, indirect evidence, inconsistency
(unexplained heterogeneity), imprecision; and publication bias.
GRADE also allows for the potential of rating up the overall qual-
ity of evidence frommethodologically sound observational studies
(Guyatt 2011). For example, evidence could be rated up if high
quality observational studies show a two- to five-fold reduction
or increase in risk (Guyatt 2011). Taking all of these factors into
account, we rated the overall quality of evidence as follows:
1. High. We are very confident that the true effect lies close to
that of the estimate of the effect;
2. Moderate. We are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different;
3. Low. Our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect; or
4. Very low. We have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
Measures of treatment effect
For binary outcomes, we calculated the risk ratio (RR) with cor-
responding 95% confidence interval (CI). For nominal or ordi-
nal outcomes, we planned to calculate the RR with corresponding
95% CI for each category relative to a reference category. For con-
tinuous outcomes, we calculated the mean difference (MD) and
corresponding 95% CI.
Unit of analysis issues
The unit of analysis was the individual participant. We planned
to include cross-over trials if data were available from the first
phase of the study (i.e. before cross-over occurred). For outcomes
where events recur (e.g. clinical relapses, adverse events), we cal-
culated the proportion of patients who experienced at least one
event, individual events were not counted separately. The studies
were otherwise not anticipated to have repeated observations of
outcomes or multiple treatment events. Ecologic studies that did
not include individual-level intervention and analyses were to be
excluded. For studies with multiple treatment arms, we only in-
cluded single pair-wise comparisons as appropriate.
Dealing with missing data
We collected information on how each trial handled missing data.
When a study appeared to collect and not report all primary out-
comes of interest, the original investigators were contacted to re-
quest missing data. If the original investigators did not provide
the data, this would be noted in the systematic review. For stud-
ies with missing dichotomous data, a separate intention-to-treat
analysis was performed where participants with missing data were
assumed to have been treatment failures. For studies with missing
continuous data, we used of available cases and imputation with
the last observation carried forward. Multiple imputation was to
be applied to missing data.
Assessment of heterogeneity
Heterogeneity was first assessed qualitatively considering the study
populations (e.g. adults, children, age, sex, race), research setting,
methods of dietary interventions, duration of interventions, and
definitions and thresholds for remission. For studies that had qual-
itative homogeneity, statistical heterogeneity was assessed using
the Chi² test (P value < 0.10 was considered statistically significant
heterogeneity). The degree of heterogeneity across studies was es-
timated using the I² statistic. An I² of 25% or less was considered
low heterogeneity, 26 to 50% was considered moderate hetero-
geneity, and 50% and greater was considered substantial hetero-
geneity. We planned to only report on summary effect estimates
from meta-analyses of groups of studies with clinical, method-
ologic, and statistical homogeneity (i.e. I² < 50%). Additionally,
we visually inspected the forest plots and planned to perform a
sensitivity analysis excluding any obvious outliers.
Assessment of reporting biases
The total number of registered trials that could qualify for inclu-
sion if published were to be compared against the number of peer-
reviewed publications. Study contacts for registered trials without
a peer-reviewed publication were to be contacted to assess reasons
for the absence of publication. If 10 of more studies were included
in the meta-analysis, a funnel plot would have been used to assess
for potential publication bias.
Data synthesis
This systematic reviewqualitatively reported on the included study
characteristics and outcomes. We conducted a meta-analysis of
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studies where at least two studies with similar interventions, par-
ticipants and reported outcomes were present (to be determined
by consensus). Analyses were performed separately according to
disease type (CD orUC), population (adult or pediatric), and type
of diet. For dichotomous outcomes, we calculated the pooled RR
and corresponding 95% CI. For continuous outcomes, we calcu-
lated the pooled MD and corresponding 95% CI. Studies were
pooled using a random-effects model. Studies were grouped ac-
cording to disease state (active or inactive) and type (UC or CD).
Subgroup analysis and investigation of heterogeneity
We planned to qualitatively evaluate the usage patterns of con-
current IBD-specific therapies (e.g. antibiotics, aminosalicylates,
immunomodulators, biologics) in the study populations. Where
possible, subgroup analyses were to be performed based on ther-
apy classes.
Sensitivity analysis
We planned to conduct sensitivity analyses that exclude studies
with high risk of bias. However, as over 70% of the studies were at
high risk of bias, there would have been little or no data to assess
in a sensitivity analysis
R E S U L T S
Description of studies
Results of the search
The literature search identified 8097 records which was reduced
to 7166 unique records following the removal of duplicates. Titles
and abstracts were screened and we initially identified 60 studies
which appeared to meet the inclusion criteria. Full text copies of
these 60 studies were obtained and further scrutinised. After re-
viewing full text articles, we excluded 35 studies which had the
wrong study design, participants, interventions or outcomes. We
included 18 studies with a total of 1878 participants in our sys-
tematic review. We also identified five ongoing studies with an
estimated enrollment of 498 participants (See Characteristics of
ongoing studies) and two studies awaiting classification (Bodini
2018; Tapete 2018). The results of the search are reported in the
PRISMA flow diagram (See Figure 2). Full details of the included
and excluded studies are available in theCharacteristics of included
studies and Characteristics of excluded studies tables and are sum-
marised below.
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Figure 2. Study flow diagram.
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Included studies
Study design and setting
The included studies were conducted in single or multi cen-
ters across eight different countries and were published between
1965 and 2018. Thirty-five per cent of the studies were con-
ducted in theUK (Jones 1985; Lomer 2001; Lomer 2005; Riordan
1993; Ritchie 1987; Wright 1965), 23% in the USA (Albenberg
2018; Bhattacharyya 2017; Brotherton 2014; Mutlu 2016), 11%
in Germany (Brandes 1981; Lorenz-Meyer 1996), 11% in Italy
(Levenstein 1985; Strisciuglio 2013) and the rest were conducted
in Austria (Bartel 2008), Canada (Keshteli 2016), Israel (Dariel
2007), and South Africa (Candy 1995).
Participants
The 18 studies included a total of 1878 randomized participants
with sample sizes ranging between 7 and 659 participants. Disease
severity was reported as mild, or mild to moderate in two studies
(Bartel 2008; Dariel 2007). The other studies did not report on
disease severity. The use of medication was apparent in some or all
participants in almost half of the studies regardless of disease type
or state. However, this information was not reported in the rest of
the studies. The age of participants was reported in all except two
studies (Albenberg 2018; Wright 1965), and ranged between an
average of 11.2 years to 48 years across 12 studies. Other studies
reported age as median (Candy 1995), or range (Bhattacharyya
2017; Jones 1985; Ritchie 1987). One study recruited only paedi-
atric patients (Strisciuglio 2013), and the rest of the studies appear
to have included mainly adults. The studies looked at people with
the following disease states and types:
• Active Crohn’s disease (Bartel 2008; Brotherton 2014;
Dariel 2007; Levenstein 1985; Lomer 2001; Lomer 2005);
• Inactive Crohn’s disease (Albenberg 2018; Brandes 1981;
Jones 1985; Lorenz-Meyer 1996; Mutlu 2016; Riordan 1993;
Ritchie 1987);
• Active ulcerative colitis (Candy 1995); and
• Inactive ulcerative colitis (Bhattacharyya 2017; Keshteli
2016; Strisciuglio 2013; Wright 1965).
Interventions
All the included studies had two trial arms, except four studies
with more than two trial arms (Lomer 2005; Lorenz-Meyer 1996;
Mutlu 2016; Wright 1965). The studies compared intervention
diets with control diets. For the purpose of this review, ’interven-
tion diet’ has been used to describe diets involving the consump-
tion of low levels or complete exclusion of one ormore food groups
that are thought to trigger symptoms of IBD (see Description
of the condition). Control diets involved normal amounts these
food groups which were restricted in the intervention group, other
diet modifications or advice. From Table 2 it is apparent that
whilst some dietary modifications were centred around single food
groups, other diets seemed to involve multiple food groups. These
interventions and controls are summarised as follows:
• Low refined carbohydrate diets (Brandes 1981; Brotherton
2014; Lorenz-Meyer 1996; Ritchie 1987). The control diets
were either intentionally rich in refined carbohydrates (Brandes
1981; Ritchie 1987), or provided no guidance on carbohydrate
intake (Brotherton 2014; Lorenz-Meyer 1996).
• Low microparticle diets (Lomer 2001; Lomer 2005). The
control diets included a sham diet that avoided other food
additives (i.e., sulphur dioxide and sulphites) and added 5 mg/
day titanium dioxide (TiO2). Toothpaste that was free of TiO2,
but not particulate silicates, was provided.
• Low calcium diet (Lomer 2005). The control diet included
a calcium supplement of 400 mg/day.
• Low red, processed meat diet (Albenberg 2018). The
control diet included a minimum of two servings per week of red
meat.
• Low disaccharides, grains, saturated fats, red and processed
meat diet (Mutlu 2016). The control diet was undefined, but
presumably included the opposite composition of the
intervention.
• Symptoms-guided diets (Candy 1995; Dariel 2007; Jones
1985; Riordan 1993). The controls arms included a high fiber
diet (Jones 1985), undefined ’conventional’ dietary advice
(Dariel 2007), no dietary modification (Candy 1995), and
corticosteroids (Riordan 1993).
• Highly restricted organic diet (Bartel 2008). The control
diet included a low-fat, low-fiber, high-carbohydrate diet.
• Milk-free diets (Strisciuglio 2013; Wright 1965). The
control diets included an unrestricted diet (Strisciuglio 2013), or
the exclusion of certain food items, such as fried foods,
condiments, and ice cream (Wright 1965).
• Alberta-based anti-inflammatory diet (Keshteli 2016). The
control diet included recommendations from the Canada Food
Guide.
• Carrageenan-free diet (Bhattacharyya 2017). The control
diet included 100 mg of encapsulated food-grade carrageenan
with each meal (Bhattacharyya 2017).
After randomisation, dietary instruction was provided by a di-
etitian or other research personnel in most studies (Bartel 2008;
Bhattacharyya 2017; Brandes 1981; Candy 1995; Keshteli 2016;
Lomer 2001; Lomer 2005; Riordan 1993; Ritchie 1987; Wright
1965). Dietary instruction was primarily provided by written ma-
terials in three studies (Brotherton 2014; Lorenz-Meyer 1996;
14Dietary interventions for induction and maintenance of remission in inflammatory bowel disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Strisciuglio 2013), and advicewas provided through unclearmech-
anisms in four studies (Albenberg 2018; Dariel 2007; Jones 1985;
Mutlu 2016).
In studies which provided some description, the intervention reg-
imen varied and there was very little information on food groups
which participants were exposed to other than the study interven-
tion. The specific proportions or concentrations of macro- and
micronutrients consumed at baseline or after randomisation were
not reported.Nonetheless, adherence to dietary recommendations
was monitored through periodic interviews inmost studies (Bartel
2008; Bhattacharyya 2017; Brandes 1981; Candy 1995; Keshteli
2016; Lomer 2001; Lomer 2005; Lorenz-Meyer 1996; Riordan
1993; Ritchie 1987). The method for assessing dietary adherence
was not reported in six studies (Albenberg 2018; Brotherton 2014;
Dariel 2007; Jones 1985; Mutlu 2016; Strisciuglio 2013).
The use of concomitant treatments was discussed in eight stud-
ies with six studies reporting the use of medication (Bartel 2008;
Lomer 2001; Lomer 2005; Lorenz-Meyer 1996; Strisciuglio 2013;
Wright 1965), one study indicating that drug treatment was omit-
ted 14 days before the study commenced (Brandes 1981), and one
study which administered prednisolone in the control arm which
was gradually withdrawn over the course of the study (Riordan
1993). There was no mention of concomitant treatments in the
rest of the studies.
Outcomes
Participants were followed up for 1 to 24 months. Outcomes of
interest reported in the studies were:
• Induction of remission (Bartel 2008; Brotherton 2014;
Candy 1995; Dariel 2007; Lomer 2001; Lomer 2005);
• Clinical relapse (Albenberg 2018; Bhattacharyya 2017;
Brandes 1981; Jones 1985; Keshteli 2016; Lorenz-Meyer 1996;
Mutlu 2016; Riordan 1993; Ritchie 1987; Strisciuglio 2013;
Wright 1965);
• Surrogate biomarkers of inflammation (Bartel 2008;
Bhattacharyya 2017; Brotherton 2014; Jones 1985; Lomer 2005;
Riordan 1993; Strisciuglio 2013);
• Endoscopic improvement (Bartel 2008; Candy 1995;
Strisciuglio 2013);
• Histologic improvement (Candy 1995; Strisciuglio 2013);
• Health-related quality of life (Bartel 2008; Bhattacharyya
2017; Brotherton 2014; Dariel 2007; Keshteli 2016; Lomer
2005);
• Need for surgery (Brandes 1981; Lomer 2001; Ritchie
1987; Levenstein 1985);
• Progression of disease (Bartel 2008; Brandes 1981;
Levenstein 1985); and
• Escalation of therapy (Levenstein 1985).
Funding and declaration of interest
Seventy-two per cent of the included studies reported no in-
formation on both funding sources and declarations of inter-
est (Albenberg 2018; Brandes 1981; Candy 1995; Dariel 2007;
Jones 1985; Keshteli 2016; Levenstein 1985; Lorenz-Meyer 1996;
Mutlu 2016; Riordan 1993; Ritchie 1987; Strisciuglio 2013;
Wright 1965). In two studies, authors had no conflicts of in-
terest, however, funding was not reported (Bhattacharyya 2017;
Lomer 2005). Three studies were funded by a stipend from a Uni-
versity (Bartel 2008), or grants from government organizations
(Brotherton 2014; Lomer 2001), however, the authors of these
studies did not declare any financial interests.
Excluded studies
Thirty-five studies were excluded for reasons which are detailed
in the Characteristics of included studies tables and summarised
below:
• Twelve excluded studies had the wrong study design
(Barnes 2016; Beattie 1994; Brandes 1982; Castro 1995;
Ciccimarra 1998; Cohen 2012; Davies 1978; Halmos 2016,
NCT02345733; NCT02922881; NCT03171246;
Pituch-Zdanowska 2018).
• Six studies either assessed a mixed population and did not
report outcomes by sub-population (Gunasekeera 2016;
Pedersen 2017; Stange 1990), or assessed IBS (Vincenzi 2016),
healthy participants (NCT02426567) or failed to provide
sufficient information on baseline disease activity (Kyaw 2014).
• Five studies assessed the wrong interventions (Boneh 2017;
Dunn 2017; El-Tahir 1998; NCT02231814; Strohm 1981).
• Five of the excluded studies failed to assess outcomes of
interest (Bentz 2010; Mikolaitis 2013; NCT02469220; Pedersen
2014; Svolos 2016).
• Seven studies were excluded for other reasons such as lack
of response from authors who were contacted for additional
information (NCT02093780; NCT02213835; NCT02357537;
NCT02610101; NCT02930564), study abandonment
(NCT02945488) and study termination (NCT01749813).
Risk of bias in included studies
Fourteen included studies were rated as high risk of bias for one
or more items. Four studies were rated as unclear risk of bias for
two or more items. Details of the risk of bias assessment have been
presented in the Characteristics of included studies table and are
summarised below (See Figure 3).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Thirteen of the included studies were rated as unclear risk of bias
for failing to report methods used for random sequence genera-
tion and allocation concealment (Albenberg 2018; Bartel 2008;
Brotherton 2014; Candy 1995; Dariel 2007; Jones 1985; Keshteli
2016; Levenstein 1985; Lomer 2001;Mutlu 2016; Riordan 1993;
Ritchie 1987; Wright 1965). One study was judged as being at
high risk of bias for random sequence generation because a quasi-
randomized procedure (date of birth) was used to assign partici-
pants at one of the study centers (Bhattacharyya 2017). Since allo-
cation concealment is not feasible in quasi-randomized trials, we
also judged the study as being at high risk of bias for allocation
concealment. Four studies were judged as being at low risk of bias
for both sequence generation and unclear risk of bias for allocation
concealment (Brandes 1981; Lomer 2005; Lorenz-Meyer 1996;
Strisciuglio 2013).
Blinding
We judged two studies as being at low risk of performance and de-
tection bias (Mutlu 2016; Riordan 1993).WhilstMutlu 2016 was
referred to as double blind and further details were not provided,
we considered the information sufficient to make this judgement.
Performance bias
Nine studies which were not referred to as blinded were judged as
being at high risk of performance bias. Four studies only provided
information on the blinding of either the participants or study per-
sonnel but not both (Brotherton 2014; Levenstein 1985; Lomer
2001; Lomer 2005). We judged five studies as being at low risk of
bias for using some sort of ’dummy’ diet or tablet (Bhattacharyya
2017; Lorenz-Meyer 1996; Mutlu 2016; Riordan 1993; Wright
1965).
Detection bias
When assessing for detection bias, nine studies were found to be
at low risk of bias (Candy 1995; Jones 1985; Levenstein 1985;
Lomer 2001; Lomer 2005; Mutlu 2016; Riordan 1993; Ritchie
1987; Strisciuglio 2013). Eight were judged to be at unclear risk of
bias (Albenberg 2018; Bartel 2008; Bhattacharyya 2017; Brandes
1981; Dariel 2007; Keshteli 2016; Lorenz-Meyer 1996; Wright
1965). Outcome assessors were not blinded in Brotherton 2014.
Incomplete outcome data
In two studies, attrition rates were sufficiently different enough
to induce clinically relevant bias in intervention effect estimates
(Dariel 2007; Wright 1965), and in one study four times more
patients from the intervention group withdrew due to non-com-
pliance compared to the control group (Ritchie 1987). These
studies were assessed as being at high risk of attrition bias. We
found 13 studies to be at low risk of attrition bias as attrition
rates were low and balanced across groups (Bartel 2008; Brandes
1981; Candy 1995; Levenstein 1985; Lomer 2001; Lomer 2005;
Lorenz-Meyer 1996; Riordan 1993), and all participants were ac-
counted for (Brotherton 2014; Jones 1985; Keshteli 2016; Mutlu
2016; Strisciuglio 2013). Bhattacharyya 2017 was found to be at
unclear risk of attrition bias.
Selective reporting
None of the included studies had a protocol or trial registration
with the exception of Bhattacharyya 2017. Six studies were judged
as being at low risk of bias for reporting all outcomes prespec-
ified in the methods section (Brandes 1981; Brotherton 2014;
Candy 1995; Levenstein 1985; Lomer 2005, Strisciuglio 2013).
Five studies were judged to be at high risk of bias due to a study not
reporting on an outcome which was prespecified in the trial pro-
tocol (Bhattacharyya 2017), or for reporting outcomes as not sta-
tistically significant (or reporting P values) without reporting any
further data (Keshteli 2016; Lomer 2001; Riordan 1993; Ritchie
1987). The rest of the studies were judged to be at unclear risk of
bias.
Other potential sources of bias
Most of the studies (65%) were judged as being at low risk of
bias for other sources of bias as there was no indication of other
biases occurring. Five studies were at unclear risk of other bias for
not reporting information sufficient to determine whether there
were other biases (Bartel 2008; Dariel 2007; Keshteli 2016;Mutlu
2016;Wright 1965), andone studywas judged as being at high risk
of bias for including participants with significantly higher CDAI
scores in one group (Lomer 2001).
Effects of interventions
See: Summary of findings for the main comparison
Intervention diet compared to control diet for induction of
remission in active Crohn’s disease; Summary of findings 2
Intervention diet compared to control diet for maintenance of
remission in inactive Crohn’s disease; Summary of findings
3 Intervention diet compared to control diet for induction of
remission in active ulcerative colitis; Summary of findings 4
Intervention diet compared to control diet for maintenance of
remission in inactive ulcerative colitis
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Intervention diet versus control diet for the induction of
remission in active CD
Six studies compared various exclusion diets with control diets in
participants with active Crohn’s disease (Bartel 2008; Brotherton
2014; Dariel 2007; Levenstein 1985; Lomer 2001; Lomer 2005).
The exclusion diets that were assessed included low refined car-
bohydrates, low microparticle, low fiber, low calcium, symptoms-
guided and a highly restricted organic diet.
Induction of remission
The effect of low refined carbohydrates, low microparticle diet,
low calcium diet, symptoms-guided diet, and a highly restricted
organic diet on inducing remission in active CD is uncertain as
the certainty of the evidence was assessed as very low (See Analysis
1.1; Summary of findings for the main comparison).
At 4 weeks, remission was achieved by all participants (4/4) in the
high fiber, low refined carbohydrates diet group compared with
none of the participants (0/3) in the control group (RR 7.20, 95%
CI 0.53 to 97.83; 7 participants; 1 study; very low certainty ev-
idence). Forty-four per cent (23/52) of patients in the low mi-
croparticle diet group achieved remission at 16 weeks compared
to 25% (13/51) of control-group patients (RR 3.13, 95% CI 0.22
to 43.84; 103 participants; 2 studies; I² = 73%; very low certainty
evidence). Fifty per cent (16/32) of participants in the symptoms-
guided diet group achieved remission (unclear when remission was
measured) compared to 0% (0/19) of participants in the control
group (RR 20.00, 95% CI 1.27 to 315.40; 51 participants; 1
study; very low certainty evidence). Fifty per cent (4/8) of patients
in the highly restricted organic diet group achieved remission at 6
weeks (50%; 4/8) compared to 50% (5/10) of the control group
(RR 1.00, 95% CI 0.39 to 2.53; 18 participants; 1 study; very low
certainty evidence). Thirty-seven per cent (16/43) of participants
in the low calcium diet group achieved remission at 16 weeks com-
pared to 30% (12/40) of the control group (RR 1.24, 95%CI 0.67
to 2.29; 83 participants; 1 study; very low certainty evidence).
Need for surgery
The effect of a lowmicroparticle diet or a lowfiber diet on the need
for surgery is uncertain (Analysis 1.6). At 4months, the proportion
of patients who needed surgery in the low microparticle group
was 10% (1/10) compared to 0% (0/10) in the control group (RR
3.00, 95% CI 0.14 to 65.90; 20 participants ; 1 study). After
24 months, the need for surgery was reported among an equal
proportion of patients on both low fiber diet (14%; 5/30) and
control diet (14%; 4/28) diet (RR 1.17, 95% CI 0.35 to 3.91; 58
participants; 1 study).
Health related quality of life (IBDQ)
It is uncertain whether symptoms-guided or highly restricted or-
ganic diets improve health related quality of life as the certainty
of the evidence was assessed as very low (Analysis 1.5; Summary
of findings for the main comparison). The mean difference in the
IBDQ-score between the symptoms-guided diets (mean 175.9 +/
- 28.8; 32 participants) and the control diet (mean 152.15 +/-
29.6; 19 participants) (follow-up period unclear) was 23.75 (95%
CI 7.12 to 40.38; 51 participants; 1 study; very low certainty evi-
dence). The mean IBDQ score among the followers of the highly
restricted organic diet after 24 weeks was 196 (+/- 20) compared
to a mean score of 192 (SD = 20) found among the control group
(MD 4.00, 95%CI -17.86 to 25.86; 14 participants; 1 study; very
low certainty evidence).
Two studies also reported on IBDQ but did not report sufficient
information to allow for meta-analysis. Lomer 2005 measured
IBDQ scores among patients in both the low and normal mi-
croparticle diet (reported P = 0.2; 83 participants; no specific data
for either group reported) and the low versus normal calcium diet
(reported P = 0.7; 83 participants; no specific data for either group
reported) groups after 52 weeks. However, data were not suffi-
ciently reported for a meta-analysis. Brotherton 2014 reported
higher scores on the IBDQ in the intervention group over time
than those in control group during the 4-week period (reported P
= 0.028; 7 participants). Change in mean scores were reported in
the low refined carbohydrate group (44.25 points) and the control
diet (19 points). When both groups were compared, reported P =
’n.s’.
Surrogate biomarkers of inflammation
One study with 14 participants and a follow-up of 24 weeks re-
ported on CRP and ESR. It is uncertain whether highly restricted
organic diets lead to a difference in CRP (Analysis 1.2) or ESR
(Analysis 1.3). At 24 weeks, themean CRP among the followers of
the highly restricted organic diet was 1.1 mg/dL (+/- 1) compared
to a mean of 0.7 mg/dL (+/- 0.4) in the control group (MD 0.40,
95% CI -0.51 to 1.31; 14 participants; 1 study); while the mean
ESR was 15 mm/h (+/- 3) in the highly restricted organic diet
compared to a mean of 20 mm/h (+/- 20) found among the con-
trol group (MD -5.00, 95% CI -15.15 to 5.15; 14 participants; 1
study).
CRP, ESR and fecal calprotectin data in the low microparticle (42
participants) versus normal microparticle (41 participants) diet
(reported P = 0.2, 0.5 and 0.07 respectively) and among the low
calcium (43 participants) versus normal (40 participants) calcium
diet (reported P = 0.6, 0.6 and 0.9 respectively) at week 52 were
reported in Lomer 2005, however, the data were not shown.
Brotherton 2014 also measured CRP (reported P = 0.125) and
ESR (reported P = 0.788) at 4 weeks. No further details were
provided.
Endoscopic improvement
The effect of highly restricted organic diets on endoscopic im-
provement is uncertain (Analysis 1.4). At 24 weeks 60% (3/5) of
18Dietary interventions for induction and maintenance of remission in inflammatory bowel disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
participants in the highly restricted organic diet group reported
endoscopic improvement versus 11% (1/9) in the control group
(RR 5.40, 95% CI 0.74 to 39.17; 14 participants; 1 study).
Disease progression
Disease progression was reported in two studies which compared
highly restricted organic diet and low fiber diet with control diets
(Bartel 2008; Levenstein 1985). The effect of highly restricted or-
ganic diets and low fiber diet on disease progression is uncertain
(Analysis 1.7). At 24 weeks, progression of disease was reported
in 20% (1/5) of participants in the highly restricted organic diet
compared to 33% (3/9) of participants in the control group (RR
0.60, 95% CI 0.08 to 4.35; 14 participants; 1 study). After 24
months, progression of disease was reported in 37% (11/30) par-
ticipants in the low fiber diet group versus 28% (8/28) in the con-
trol (RR 1.28, 95% CI 0.61 to 2.72; 58 participants; 1 study).
Intervention diet versus control diet for the maintenance of
remission in inactive CD
Seven studies compared various exclusion diets with control equiv-
alent in inactive CD (Albenberg 2018; Brandes 1981; Jones 1985;
Lorenz-Meyer 1996; Mutlu 2016; Riordan 1993; Ritchie 1987).
The exclusion diets studied included low refined carbohydrate
diet, symptoms-guided diet, low red processed meat diet and low
disaccharides / grains / saturated fats / red and processedmeat diet.
Clinical relapse
There is no clear difference in clinical relapse rates when low re-
fined carbohydrate diets, symptoms-guided diets and low red pro-
cessed meat diets are compared with control diet. The certainty of
the evidence is judged as low (Analysis 2.1; Summary of findings
2).
At 12 to 24 months, the proportion of participants with clinical
relapse in the low refined carbohydrate group was 67% (176/
264) compared to 64% (193/303) in the control group (RR 1.04,
95% CI 0.87 to 1.25; 567 participants; 3 studies; I² = 35%; low
certainty evidence). In the symptoms guided diet clinical relapse
was reported in 48% (24/50) of participants compared to 83%
(40/48) of participants in the control diet at 6 to 24 months (RR
0.53, 95% CI 0.28 to 1.01; 98 participants; 2 studies; I² = 54%;
low certainty evidence). At 48 weeks, 66% (63/96) of participants
in the low red processed meat diet group relapsed compared to
63% (75/118) in the control group (RR 1.03, 95% CI 0.85 to
1.26; 214 participants; 1 study; I² = 0%; low certainty evidence).
At 12 months, an exclusion diet of low disaccharides / grains /
saturated fats / red and processed meat resulted in no clinical
relapse (0/16) compared to 26% (10/38) among the control group
(RR 0.11, 95% CI 0.01 to 1.76; 54 participants; 1 study; very low
certainty evidence).
We carried out sensitivity analyses based on per-protocol data and
fixed-effect model. In both instances we found that the effect of
symptoms-guided diets on clinical relapse was uncertain.
Need for surgery
It is uncertain whether low refined carbohydrate diets reduce the
need for surgery (Analysis 2.4). After 24 months, surgery appeared
to be necessary for 4% (8/200) of the participants following a low
refined carbohydrate diet compared to 9% (16/172) of control
group participants (RR 0.44, 95% CI 0.19 to 1.00; 372 partici-
pants; 2 studies; I² = 0%).
Escalation of therapy
Riordan 1993 reported on escalation of therapy and it is uncer-
tain whether low refined carbohydrate diet reduces the incidence
of escalation of therapy (Analysis 2.6). Escalation of therapy was
reported for 10% (1/10) of the participants in the low refined car-
bohydrate group compared to none (0/10) in the control group
(RR 3.00, 95% CI 0.14 to 65.90; 20 participants; 1 study).
Withdrawals due to adverse events
Withdrawals due to adverse events were reported in one study
with 78 participants during 24 months of follow-up. We are un-
certain whether symptoms-guided diets reduce withdrawals due
to adverse events (Analysis 2.7). None (0/40) of the participants
in the symptoms-guided diet group withdrew from the study due
to adverse events compared to 5% (2/38) of the participants from
the control diet (RR 0.19, 95%CI 0.01 to 3.84; 74 participants; 1
study). Both of the patients in the control group were withdrawn
due to steroid side effects.
Surrogate markers of inflammation
Riordan 1993 assessed the effect of symptoms-guided diets on
CRP ( Analysis 2.2). After 24 months, participants in the symp-
toms-based diets had mean CRP scores of 2.71 mg/dL (+/- 6.58)
compared to 2.42 mg/dL (+/- 2.9) in the control group (MD0.29,
95% CI -1.95 to 2.53; 78 participants; 1 study).
Evidence from two studies shows that the effect of symptoms-
guided diets on ESR is uncertain (Analysis 2.3). The mean ESR
value during a follow-up of 6 to 24 months, was 27.6 (SD = 24.7)
mm/h among the symptoms-guided diet followers and 33.2 (SD
= 26.6) mm/h in the control diet group (MD -7.29, 95% CI -
17.22 to 2.64; I² = 0%; 95 participants; 2 studies; low certainty
evidence).
Riordan 1993 indicated that participants in the intervention group
had improved CRP concentrations. No further details were pro-
vided.
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Disease progression
It is uncertain whether low refined carbohydrate diets reduce dis-
ease progression (Analysis 2.5). At the end of the 24-month fol-
low-up period, disease progression was reported in 20% (1/5) of
the participants on low refined carbohydrate compared to 17%
(1/6) on the control diet (RR 1.20, 95% CI 0.10 to 14.69; 11
participants; 1 study).
Intervention diet versus control diet for the induction of
remission in active UC
One study assessed a symptoms-guided diet in participants with
active UC (Candy 1995).
Induction of remission
It is uncertain whether symptoms-guided diets improve the induc-
tion of remission as the certainty of the evidence has been assessed
as very low (Analysis 3.1; Summary of findings 3). After six weeks,
symptoms-guided diet led to induction of remission among 36% (
4/11) of symptoms-guided diet participants compared to none (0/
10) of the participants in the control dietary arm (RR 8.25, 95%
CI 0.50 to 136.33; 21 participants; 1 study; very low certainty
evidence).
Clinical improvement
It is uncertain whether symptoms-guided diets lead to clinical
improvement (Analysis 3.2). After six weeks of symptoms-guided
diets, 45% (5/11) of participants achieved clinical improvement
versus 10% (1/10) in the control group (RR 4.55, 95% CI 0.63
to 32.56; 21 participants; 1 study).
Endoscopic improvement
Whether symptoms-guided diets lead to endoscopic improvement
remains uncertain (Analysis 3.3). At 6 weeks, endoscopic improve-
ment was achieved by 45% (5/11) of patients on a symptoms-
guided diet compared to 10% (1/10) of the control group (RR
3.64, 95% CI 1.00 to 13.23; 21 participants; 1 study).
Histologic improvement
The impact of symptoms-guided diets on histologic improvement
is uncertain (Analysis 3.4). At 6 weeks, 27% (3/11) of participants
in the symptoms-guided diet group improved histologically com-
pared to 30% (3/10) of the control group (RR 0.91, 95% CI 0.24
to 3.51; 21 participants; 1 study).
Intervention diet versus control diet for the maintenance of
remission in inactive UC
Four studies compared various exclusion diets with control diets
in participants with inactive UC (Bhattacharyya 2017; Keshteli
2016; Strisciuglio 2013;Wright 1965). The exclusiondiets studied
included the Alberta-based anti-inflammatory diet (Bhattacharyya
2017), a Carrageenan-free diet (Keshteli 2016), and a milk-free
diet (Strisciuglio 2013; Wright 1965).
Clinical relapse
All four studies reported on clinical relapse, but it is uncer-
tain whether the Alberta-based anti-inflammatory diet, the Car-
rageenan-free diet or the milk free diet reduces clinical relapse,
as the certainty of the evidence was assessed as very low or low
(Analysis 4.1; Summary of findings 4). At 6 months, the Alberta-
based anti-inflammatory diet led to clinical relapse in 36% (5/14)
of patients in comparison to 29% (4/14) of control participants
(RR 1.25, 95% CI 0.42 to 3.70; 28 participants; 1 study; very low
certainty evidence). Thirty per cent (3/10) of patients following
the carrageenan-free diet for 12 months reported clinical relapse
compared to 60% (3/5) of the control group participants (RR
0.50, 95% CI 0.15 to 1.64; 15 participants; 1 study; very low
certainty evidence). At 12 months, 59% (23/39) of milk free diet
participants relapsed compared to 68% (26/38) of control diet
participants (RR 0.83, 95% CI 0.60 to 1.15; 77 participants; 2
studies; I² = 0%; low certainty evidence).
Endoscopic relapse
Mean endoscopic Matt colonoscopy grading scores (0 to 4;
higher score = increased severity; Matt 1961) were reported by in
Strisciuglio 2013 (mean change score: reported P = 0.5; 29 par-
ticipants) after 12 months for the milk -free diet and control diet,
however, data were not sufficient for a statistical analysis.
Histologic relapse
Mean histologic Matt scores at 12 months were reported in
Strisciuglio 2013 (mean change score: reported P = 0.4; 29 partic-
ipants) for the milk -free and control dietary arms, however, data
were not sufficiently reported for a statistical analysis.
Surrogate inflammatory biomarkers
One studywith 12 participants (Bhattacharyya 2017), reported on
fecal calprotectin (Analysis 4.2), IL-6 (Analysis 4.4), IL-8 (Analysis
4.5) and TNF-α (Analysis 4.3) and it is uncertain whether car-
rageenan-free diets improve these parameters. At 12 months, the
mean difference in the levels of these parameters between the car-
rageenan and the control group were as follows: fecal calprotectin
60.00 g/gm (95%CI -59.24 to 179.24); IL-6 1.94 pg/ml (95%CI
-0.35 to 4.23); IL-8 38.00 pg/ml (95%CI -139.24 to 215.24) and
TNF-α -4.50 pg/ml (95% CI -8.92 to -0.08). After 12 months,
median and range of CRP (reported P = 0.6), ESR (reported P =
0.3) and FC (reported P = 0.3) were reported in Strisciuglio 2013,
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however, as measures of variance were not reported, we were un-
able to analyse the results further.
Health related quality of life (SIBDQ)
It is uncertain whether carrageenan-free diets improve health re-
lated quality of life as the certainty of the evidence has been assessed
as very low (Analysis 4.6).The mean difference in the SIBDQ be-
tween the carrageenan group and the non-carrageenan group at
12 months was -1.70 (95% CI -8.23 to 4.83; 12 participants; 1
study; very low certainty evidence).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intervention diet compared to control diet for maintenance of remission in inactive Crohn’s disease
Patient or population: people with inact ive Crohn’s disease
Setting: home
Intervention: intervent ion diet (various)
Comparison: control diet (various)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with control diet Risk with intervention
diet
Clinical relapse at 12 to
24 months - Low ref ined
carbohydrate diet
Study populat ion RR 1.04
(0.87 to 1.25)
567 (3 studies) ⊕⊕©©
LOW1,2
Relapse was def ined as
CDAI > 150
637 per 1,000 662 per 1,000
(554 to 796)
Clinical relapse at 6 to
24 months - Symptoms-
guided diet
Study populat ion RR 0.53
(0.28 to 1.01)
98 (2 studies) ⊕⊕©©
LOW1,3
Relapse was def ined as
CDAI > 150
833 per 1,000 442 per 1,000
(233 to 842)
Clinical relapse at 48
weeks - Low red, pro-
cessed meat diet
Study populat ion RR 1.03
(0.85 to 1.26)
214 (1 study) ⊕⊕©©
LOW1,4
Relapse was def ined as
CDAI > 150
636 per 1,000 655 per 1,000
(540 to 801)
Clinical relapse at 12
months - Exclusion
diets (low disaccha-
rides, grains, saturated
fats, red and processed
meats)
Study populat ion RR 0.11
(0.01 to 1.76)
54 (1 study) ⊕©©©
VERY LOW1,5
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263 per 1,000 29 per 1,000
(3 to 463)
Health-related quality
of lif e
None reported in any of the studies
Adverse events None reported in any of the studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; CDAI: Crohn’s disease act ivity index.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high or unclear risk of bias
2 Downgraded one level due to imprecision (369 events)
3 Downgraded one level due to imprecision (64 events)
4 Downgraded one level due to imprecision (138 events)
5 Downgraded two levels due to serious imprecision (10 events)
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Intervention diet compared to control diet for the induction of remission in active ulcerative colitis
Patient or population: people with act ive ulcerat ive colit is
Setting: home
Intervention: intervent ion diet (various)
Comparison: control diet (various)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with control diet Risk with intervention
diet
Induct ion of remission -
Symptoms-guided diet
Study populat ion RR 8.25
(0.50 to 136.33)
21 (1 study) ⊕©©©
VERY LOW1,2
We were unable to cal-
culate absolute ef fects.
Remission was induced
in 36% (4/ 11) of symp-
toms-guided diet par-
t icipants compared to
0%(0/ 10) of the control
group
Remission was def ined
as passage of normal
stools with absence of
rectal bleeding
0 per 1,000 0 per 1,000
(0 to 0)
Health-related quality
of lif e
Not reported in any of the studies
Adverse events Not reported in any of the studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high or unclear risk of bias
2 Downgraded two levels due to serious imprecision (4 events)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Intervention diet compared to control diet for maintenance of remission in inactive ulcerative colitis
Patient or population: Part icipants with inact ive ulcerat ive colit is
Setting: home
Intervention: Intervent ion diet (various)
Comparison: control diet (various)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with control diet in
inactive ulcerative col-
itis
Risk with Intervention
diet
Clinical relapse at 6
months - Ant i-inf lam-
matory diet (Alberta-
based)
Study populat ion RR 1.25
(0.42 to 3.70)
28
(1 RCT)
⊕©©©
VERY LOW1,2
Relapse was def ined by
a Mayo score > 3
286 per 1,000 357 per 1,000
(120 to 1,000)
Clinical relapse at 12
months - Carrageenan-
f ree diet
Study populat ion RR 0.50
(0.15 to 1.64)
15
(1 RCT)
⊕©©©
VERY LOW1,3
Relapse was def ined by
an increase in the Sim-
ple Clinical Colit is Ac-
t ivity Index of > 2 points
600 per 1,000 300 per 1,000
(90 to 984)
Clinical relapse at 12
months - Milk f ree diet
Study populat ion RR 0.83
(0.60 to 1.15)
77
(2 RCTs)
⊕⊕©©
LOW1,4
Relapse was def ined
by a Pediatric Ulcera-
t ive Colit is Act ivity In-
dex score > 10 points or
by clinical symptoms (4
or more diarrhea move-
ments per day with vis-
ible blood)
684 per 1,000 568 per 1,000
(411 to 787)
Health related quality
of lif e at 12 months -
SIBDQ - Carrageenan-
f ree diet
The mean health re-
lated quality of lif e -
SIBDQ was 0
MD 1.7 higher
(4.83 lower to 8.23
higher)
- 12
(1 RCT)
⊕©©©
VERY LOW1,5
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Adverse events Not reported in any of the studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; SIBDQ: Short Inf lammatory Bowel Disease Quest ionnaire; MD: Mean dif ference
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high or unclear risk of bias
2 Downgraded two levels due to serious imprecision (9 events)
3 Downgraded two levels due to serious imprecision (6 events)
4 Downgraded one level due to imprecision (49 events)
5 Downgraded two levels due to very serious imprecision (12 part icipants)
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D I S C U S S I O N
Summary of main results
We included 18 randomized controlled trials (1878 randomized
participants) that assessed dietary interventions for the induction
and maintenance of remission in IBD. The trials were subdivided
into groups based on disease state and type: active CD, inactive
CD, activeUC and inactiveUC.The dietary interventions studied
involved some dietary restriction or exclusion of single or multiple
food components which are believed to trigger IBD symptoms or
inflammation. The diets were so varied that there was little scope
for pooling data.
Induction and maintenance of remission in Crohn’s disease
There is insufficient evidence to determine whether exclusion diets
(low refined carbohydrates, low microparticle, symptoms-guided
diet, highly restricted organic diet and low calcium diet) improve
clinical remission rates in active Crohn’s disease as the certainty of
the evidence was assessed as very low.
When we looked at the evidence for inactive Crohn’s disease, there
was little or no difference in clinical relapse rates when exclusion
diets (low refined carbohydrates, symptoms-guided and low red/
processed meat diet) were compared with control diets. The cer-
tainty of the evidence was low due to risk of bias and imprecision.
On the other hand, we found insufficient evidence to determine
whether low disaccharides/low grain/low saturated fats/low red
and processed meat diet reduces clinical relapse as the certainty of
evidence was assessed as very low.
Other than two participants being withdrawn for steroid-related
side effects in a small maintenance of remission study (Riordan
1993), none of the studies assessing diet inCD reported on adverse
events.
Induction and maintenance of remission in ulcerative colitis
There was insufficient evidence on whether symptoms-based diets
improve clinical remission rates in active ulcerative colitis (very
low certainty).
We found very low certainty evidence from two trials which was
insufficient to determine whether the Alberta-based anti-inflam-
matory diet, or a Carrageenan-free diet reduce clinical relapse rates
in inactive ulcerative colitis.We found low certainty evidence from
two studies which was insufficient to determine if a milk-free diet
reduces clinical relapse rates in inactive ulcerative colitis.
None of the studies assessing diets in UC reported on adverse
events.
Overall completeness and applicability of
evidence
The evidence was very limited due to the initial clinical design,
specific interventions and choice of populations. In particular, sev-
eral studies do not describe in much detail the actual dietary ma-
nipulations used. As this almost excludes any form of true dis-
semination and replication, the applicability is severely hampered.
Examples include high fiber + reduced refined carbohydrate, low
carbohydrate + high protein and fat, milk-free + low-roughage,
low disaccharides + low grains + low saturated fats + low red and
low processed meat. This is further exemplified in the results of
one intervention which showed a potential efficacious outcome
in the context of symptoms-guided diet. As this is a very subjec-
tive dietary therapy and no national or international consensus or
evidence-based method, framework or evidence was cited in the
individual studies, further local research or practice in this area is
also severely hampered. All the studies in this review except one,
are based on an adult population with little or no information on
severity of disease.
It is a real concern that no adverse events related to the inter-
ventions were discussed in any of the studies. Patients who access
information from different media which promote dietary inter-
ventions based on these studies and try these diets, need to be
informed of any adverse effects yet this vital piece of information
is absent.
Quality of the evidence
The included studies lacked homogeneity of any sort and were
methodologically flawed resulting in very heterogenous data that
were difficult to analyse or summarise. This resulted in our down-
grading the evidence to low or very low certainty. Another con-
tributing factor was the lack of information to assess risk of bias
and high risk of bias resulting from the difficulty in blinding par-
ticipants and personnel to dietary interventions. Most of the stud-
ies had small sample sizes and sparse data with the smallest study
having as few as seven participants. We found that having inade-
quately powered heterogenous studies with limited scope for pool-
ing, resulted in mostly imprecise results.
There was no indirectness as the included studies were all within
the scope of the review. Having a limited number of studies pre-
cluded our assessment of publication bias.
Potential biases in the review process
We acknowledge that there are certain decisions which were made
during the review process which may have introduced bias in the
results. For instance, some studies reported results whichwe had to
estimate visually from graphs. Using this method may have led to
inaccuracies; however, having counter measures, such as extract-
ing the data in duplicate coupled with additional checking from
other members of the author team, is likely to have minimised
error. Again, the differences in dietary interventions may have led
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to the misclassification of diets resulting in erroneous pooling of
clinically heterogenous study data. This has been a consequence
of the plurality, lack of consensus and insufficient reporting of
trial interventions among study investigators. These obvious dif-
ferences in interventions and controls highlighted meant that we
rarely downgraded evidence for unexplained heterogeneity (incon-
sistency). However, as most of the evidence was of very low cer-
tainty and obtained from single trials, this may not be a source of
concern as a further downgrade of the certainty of evidence would
not change the interpretation of the results.
Agreements and disagreements with other
studies or reviews
Although it was recommended in the NICE guideline that peo-
ple with Crohn’s disease be given information on diet and nutri-
tion, no details were provided on what the diets should be (NICE
2016). There is also no indication that this recommendation is
based on systematic review evidence. There are currently no other
systematic reviews assessing dietary interventions for induction
andmaintenance of remission in IBD. Compared to other studies,
it is important to note that RCTs which have evaluated symptoms-
guided diets in active and inactive CD (Dariel 2007; Jones 1985;
Riordan 1993), when analyzed individually, all show that the diet
offers an advantage for the induction and maintenance of remis-
sion in CD. However, the evidence from our review was insuffi-
cient to support the use of symptoms-guided diets. This could be
an area for future research as more studies are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The effects of dietary interventions on CD and UC are uncertain.
Thus no firm conclusions regarding the benefits and harms of
dietary interventions in CD and UC can be drawn. This evidence
was of very low certainty due to sparse data from heterogenous
studies which had limited scope for pooling. Adverse effects of the
interventions were not reported.
Implications for research
There is need for consensus on the composition of dietary inter-
ventions in IBD and more RCTs are required to evaluate these in-
terventions. Around 15% of the excluded studies which otherwise
would have met the inclusion criteria had mixed populations of
participants with UC and CD and did not report separate results
for each group. As a result, these studies did not contribute to
the sum of synthesised evidence. Future studies must treat these
populations separately to allow meaningful interpretations to take
place.
We need researchers to agree to a standardized, dietetically in-
formed, framework or protocol for such diets being explored in
RCTs to allow the wider research community to collaboratively
and iteratively build on each others’ research. Future RCTs need
to report sufficient details on randomization, allocation conceal-
ment, blinding of outcome assessors and outcomes including ad-
verse events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Albenberg 2018
Methods Study design: RCT (Abstract)
Setting: USA; Recruited from CCFA (Crohn’s & Colitis Foundation of America) Part-
ners, an internet-based cohort of IBD patients
Participants State of disease / disease type: Inactive / CD
Inclusion: Individuals who were in remission (abbreviated Crohn’s Disease Activity
Index [aCDAI] ≤ 150) and who reported consumption of red meat at least once weekly
Exclusion: Not stated
Age: Not stated
Sex: Not stated
Disease location: Not stated
Medication use: Not stated
Length of remission at study entry: Not stated
Number randomized (n = 659):Not stated (Group 1) / Not stated (Group 2). Among
randomized participants who consented (n = 214) - 96 (Group 1) / 118 (Group 2)
Number analyzed: Not stated
Post-randomisation exclusion (n = 445): 445 randomized subjects did not consent to
participation in study
Interventions Group 1: Not more than 1 serving per month of red or processed meat for 48 weeks
Group 2:Minimum of 2 servings per week of red or processed meat for 48 weeks
All participants: Not stated
Outcomes Duration of follow-up: 48 weeks
1. Relapse (a CDAI > 150 and increase in a CDAI by 70 points)
2.Moderate/severe relapse (aCDAI>219or need forCDsurgery or newCDmedication)
Notes Funding source: Not stated
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were reportedly randomized to
study groups
The method of randomization was not re-
ported
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
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Albenberg 2018 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, however, it is unlikely that
blinding was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Abstract publication - dropouts were not
described
Selective reporting (reporting bias) Unclear risk Primary outcome was incompletely re-
ported in the abstract, but additional de-
tails were obtained after contacting the au-
thors
Other bias Low risk Quote: “Baseline characteristics were simi-
lar in each arm and among those who con-
sented versus non-participants”
Bartel 2008
Methods Study design: RCT
Setting: Austria
Participants State of disease / disease type: Active / CD
Inclusion: Mild-to-moderate active CD (CDAI 150 - 220) with ulceration of the left-
sided colon or a significant lesion of the small bowel or right-sided colon that was
assessable by means of MRI
Exclusion: Signs or symptoms that needed operation within 1 week, obvious lack of
compliance with any of the diet regimens (e.g., vegetarians), BMI < 18, accidental weight
loss of > 5% in the last 3 months, therapy with prednisone > 25 mg or any dose equal or
below that had been adjusted during the previous 4 weeks, budesonide or mesalamine
that had been adjusted during the same period, azathioprine or anti-TNF therapy that
had been initiated or changed during the previous 3 months, or concomitant antibiotic
or probiotic therapy
Age: 48 ± 14.7 years
Sex (M:F): 9:5
Disease location: Not stated
Medication use: Mesalazine (6); Prednisolone (1); Budesonide (4); Azathioprine (4);
Infliximab (1)
Length of remission at study entry: Not applicable
Number randomized (n = 18): 8 (Group 1) / 10 (Group 2)
Number analyzed (n = 14): 5 (Group 1) / 9 (Group 2)
Post-randomisation exclusion (n = 4): Reluctant to follow strict diet (3 in Group 1);
ineffective diet (1 in Group 2)
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Bartel 2008 (Continued)
Interventions Group 1: Restricted organic diet - highly restricted diet composed of red meat, certain
sourdough bread, and small amounts of rape oil (for frying the meat) and fresh but-
ter, all from intensively monitored organic farming (avoidance of chemical fertilisation,
pesticides, genetically manipulated crops, food processing, gamma irradiation, chemical
preservation, or industrial food additives). Only plain tap water and organic tea were
allowed for drinking and rock salt (halite) was allowed for spicing. Fruits and vegetables
were excluded from the diet. Baking soda toothpaste was given for dental care. Partici-
pants were told to avoid the use of dishwasher, limit dishwashing-soap, and rinse places
with water. Betweenweeks 6 and 24, participants were instructed to add other food items
and drinks, derived from organic farming (local fruits and vegetables, dairy products,
beer, wine, honey, etc.). Refined sugar and ready-made canned or frozen food were not
allowed
Group 2: Low-fat, high-carbohydrate diet that is complete in nutrients. No fiber-rich
fruits, vegetables, or red meat were allowed. From weeks 6 to 24, participants were
instructed to eat redmeat but still to avoid fiber-rich andhard fibrous fruits and vegetables
All participants: Both groups received 3 intramuscular multivitamin injections (vita-
min B complex and vitamin C) at weeks 0, 3, and 6. All participants received dietary
counselling by a single dietician. No change in concomitant therapy was made during
the study. Where symptoms of CD deteriorated (CDAI increase by > 70 points from
baseline for 2 weeks) or a change in medication was necessary, the patient was withdrawn
from the study. Both groups were contacted by the dietician 1 week after the initial
counselling and at weeks 3 and 6. Participants had 2 more dietary counsels at weeks 12
and 24
Outcomes Duration of follow-up: 24 weeks
1. Improvements in MRI, endoscopy, and transabdominal bowel sonography scores
2. CDAI
3. Inflammatory parameters (CRP, ESR, α-1-acid glycoprotein)
4. IBDQ
5.Nutritional status assessed usingBMI, total protein, albumin, cholesterol, triglycerides,
ferritin, transferrin
Notes Funding source:G.B. received a student stipend from theMedical University of Vienna
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eighteen patients were randomly as-
signed to receive either the active or the control
diet at a 1:1 ratio”
Comment: Insufficient information on how this
was performed
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment
were not reported
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Bartel 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Only the study coordinator and the dietician
were aware of the group assignment
There is no information to suggest that partici-
pants where blinded to the intervention they re-
ceived
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated. However, outcomes using MRI were
assessed blindly
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were balanced across group
Selective reporting (reporting bias) Unclear risk Trial registration/protocol not available. It was
not specified in the Methods section that remis-
sion would be reported
Other bias Unclear risk Baseline characteristics partially reported and
did not account for the participants who were
excluded post-randomisation
Bhattacharyya 2017
Methods Study design: RCT
Setting: USA
Participants State of disease / disease type: Inactive / UC
Inclusion: A biopsy-confirmed diagnosis of ulcerative colitis in patients >18; previous
need for corticosteroids to obtain remission; in clinical remission off corticosteroids for
at least one month; SCCAI score ≤ 2; on no medications or stable dose of maintenance
medication; and willingness to follow a carrageenan-free diet for 12 months
Exclusion: ActiveUCon corticosteroids; unable to read labels on food products; inability
to make choices about diet
Age: 34 - 65 years
Sex (M:F): 8:4
Disease location: Not stated
Medication use: None (2); Mesalamine (5); Sulfasalazine (2); Thiopurine (4); Adali-
mumab (3)
Length of remission at study entry: Not stated
Number randomized (n = 15): 10 (Group 1) / 5 (Group 2)
Number analyzed (n = 12): 7 (Group 1) / 5 (Group 2)
Post-randomisation exclusion (n = 3): 3 patients in Group 1 did not receive allocated
intervention, citing reluctance to comply
Interventions Group 1: Carrageenan-free diet + placebo (dextrose)
Group 2:Carrageenan-free diet + carrageenan-containing capsules - initially one capsule
daily (100 mg), and increased intake to two capsules (200 mg) daily after finding that
one capsule daily was well-tolerated
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Bhattacharyya 2017 (Continued)
All participants: All participants were instructed by study investigators and/or partici-
pating dieticians in the carrageenan-free diet
Outcomes Duration of follow-up: 12 months (or study was curtailed when statistical significance
in relapses between the two groups was demonstrated
1. Relapse - defined as an increase of 2 or more points on the SCCAI in association with
an increase in treatment (either an increase in maintenance medication dose or addition
of new therapies for flare) by the participant’s personal physician for manifestations of
UC
2. Inflammatory biomarkers (serum Interleukin-8, interleukin-6, tumor necrosis fac-
tor-α, monocyte chemoattractant protein-1, leukocyte nuclear factor-kappaB, B-cell
leukemia/lymphoma 10, fecal calprotectin
3. SIBDQ
Notes Funding source: Not stated
Conflict of interest: Authors declared no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Two randomization schemes were used
due to convenience. Randomization at UIC was
performed by a UIC investigational pharmacist
who had no contact with the study participants.
Allocation to study tablets #1 or #2 was performed
by using a randomization table (www.randomiza-
tion.com) in which the next available treatment
was assigned to the next study enrollee. Within a
block of ten subjects, an equal number of assign-
ments to #1 or #2 was allocated. Randomization
at U of C was performed by a blinded investiga-
tor, who allocated assignment based on the partic-
ipant’s year of birth [odd or even; #1 or #2].”
Comment: Both centres used different methods
of randomisation. The University of Illinois at
Chicago (UIC) used an adequate method of ran-
domisation, while participants at the University of
Chicago (U of C) were quasi-randomized
Allocation concealment (selection bias) High risk Quote: “Randomization at U of C was performed
by a blinded investigator, who allocated assignment
based on the participant’s year of birth [odd or
even; #1 or #2]”
Comment: Quasi-randomisation where allocation
could have been predicted
Quote: “Randomization at UIC was performed by
a UIC investigational pharmacist who had no con-
tact with the study participants”
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Bhattacharyya 2017 (Continued)
Comment: Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants were randomized to receive
either capsules containing 100 mg of food-grade
carrageenan or similar appearing dextrose-contain-
ing capsules”
Comment: Placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Similar to participants, there was insufficient in-
formation on whether outcome assessors were suf-
ficiently blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Three participants in the intervention group did
not wish to comply with the diet and dropped out
before receiving the intervention
Selective reporting (reporting bias) High risk Protocol available (NCT01065571). However, the
prespecified primary outcome of time to relapse
was not reported in the publication
Other bias Low risk Groups well-balanced with no statistical differ-
ences in any parameter at baseline
Brandes 1981
Methods Study design: RCT
Setting: Germany
Participants State of disease / disease type: Active and inactive / CD*
Inclusion: Patients with radiographic, endoscopic, and/or histologically confirmed CD
who could not be included in another European multi-center CD study and has had
CD > 2 years; at least 14 days after discontinuation of all medications
Exclusion: Patients with CDAI > 200 points; treatment failures (i.e., patients who have
undergone surgery or whose activity index increased due to recurrence of disease > 250
points or with persistent duration of > 3 months between 200 to 250 points)
Age: 32 years (Group 1) / 35 (Group 2)
Sex (M:F): 13:7
Disease location: Ileal: Ileum only (10); colon only (3); ileum and colon (7)
Medication use: Sulphasalazine (1); Corticosteroids (2); Sulphasalazine + corticosteroids
(8); Corticosteroids + azathioprine (9);
Length of remission at study entry: Not stated
Number randomized (n = 20): 10 (Group 1) / 10 (Group 2); stratified by disease activity
CDAI 0 - 100: 5 (Group 1) / 6 (Group 2); CDAI 101 - 200: 5 (Group 1) / 4 (Group 2)
Number analyzed (n = 17): 10 (Group 1) / 10 (Group 2)
Post-randomisation exclusion (n = 3): 3 patients no longer followed the diet
Interventions Group 1: Low carbohydrate diet with a relative increase in protein and fat intake, with
macronutrient nutrient ratio approx 45% carbohydrates, 25% protein, and 30% fat.
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Foods and beverages with a high content of refined carbohydrates were forbidden. The
residual content of carbohydrates contained largely natural, non-refined carbohydrates
Group 2: Carbohydrate-rich diet with relative reduction in protein and fat intake. The
nutrient ratios were approximately 60% carbohydrates, 15% protein, and 25% fat. The
difference in carbohydrate content from Group 1 consisted exclusively of foods and
drinks with high levels of refined carbohydrates
All participants: Drug treatment was omitted 14 days before commencement of the
study. Depending on body weight, a high-calorie or low-calorie diet was prescribed. All
patients were advised in detail by a dietician. Each patient received a recipe for the diet
with several days’ worth of cost-cutting suggestions and a list of permitted and prohibited
foods. For each ambulatory visit, a targeted survey was performed to assess adherence
to the assigned diet. Patients who did not adhere to the prescribed diet for at least 12
months were withdrawn from the study
Outcomes Duration of follow-up: 24 months (average of 18 months)
1. CDAI (patients withdrawn from the study if they had to undergo surgery or whose
CDAI > 250 due to a relapse of the disease and persisted between 200 - 250 for longer
than three months)
2. Blood markers
Notes Funding source: Not stated
Conflict of interest: Not stated
*Participants were stratified by disease activity CDAI 0 - 100 and CDAI 101 - 200.
While those with CDAI 0 - 100 were regarded as having inactive CD (remission), those
with CDAI 101 - 200 were classed as moderate. Due to lack of clarity we focused only
on data from those with inactive remission (11 participants)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation in two diet
groupswas carried out with randomnumbers”
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment
were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated. However, it is unlikely that blind-
ing was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information on blinding of outcome assessors
not provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low and balanced across
groups.
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Selective reporting (reporting bias) Low risk All outcomes stated in the Methods section
assessed and reported
Other bias Low risk Groups well-balanced with no statistical dif-
ferences in any parameter at baseline.Noother
apparent sources of bias detected
Brotherton 2014
Methods Study design: RCT
Setting: USA
Participants State of disease / disease type: Active / CD
Inclusion: Diagnosed with CD through colonoscopy and biopsy; aged 18 to 64 years;
partial HBI (pHBI) score ≥3 and at least 4 weeks of stable pharmacologic therapy
Exclusion: Short bowel syndrome, diverticulitis, or any othermajor diagnosis that affects
the GI tract; special dietary restrictions; mental, emotional, cognitive, or other disorders
that might interfere with the ability to independently follow detailed dietary instructions
over time; cancer; pregnancy; unstable or uncontrolled kidney or cardiovascular disease;
decompensated liver disease; penetrating CD; clinically significant stricturing CD; a
pHBI score >9; use of biologic drugs
Age: 29.5 ± 13.6
Sex (M:F): 1:6
Disease location: Not stated
Medication use: Not stated
Number randomized (n = 7): 4 (Group 1) / 3 (Group 2)
Number analyzed (n = 7): 4 (Group 1) / 3 (Group 2)
Post-randomisation exclusion: None
Interventions Group 1: Specific instructions and general tips to increase whole wheat bran and reduced
refined carbohydrate intake. Examples of specific instructions were (a) to eat one packet
of whole wheat bran cereal (½ cup) each day (supplied by the study coordinator) and
(b) to drink at least 48 ounces of unsweetened fluids each day. Examples of general tips
included (a) ideas for saving money while purchasing nutritious whole foods and (b)
how to recognize added sugar in commercial food products
Group 2: Specific instructions and general tips suggested by experiences of individuals
who have used trigger identification for CD symptom control and who have avoided
consumption of dietary fiber Examples of specific instructions were (a) to avoid whole
grains, dairy products, and spicy foods on symptomatic days and (b) to drink at least 48
ounces of fluid each day, but limit fluids to sips within 30 minutes of meals. Examples of
general tips were (a) how to recognize whole grain food products and (b) how to calculate
grams of fiber consumed each day
All participants: Each participant received dietary instructions in the form of a take-
home sheet that was printed in the front of the Daily Diary
Outcomes Duration of follow-up: 4 weeks
1. Remission (defined as IBDQ ≥170 points) and clinical improvement (IBDQ score
change ≥ 32 is considered to be a clinically significant response)
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2. CRP
3. ESR
4. IBDQ
5. pHBI
Notes Funding source:Grant number 5-F31-NRO11121 from theNational Institute ofNurs-
ing Research (NINR) at the National Institutes of Health
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: Each enrolled participant was randomized
to receive either the dietary fiber instruction or the
control diet instruction
Comment: Insufficient information
Allocation concealment (selection bias) Unclear risk Themethods used for allocation concealment were
not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “participants were not informed that there
were two groups because the researchers sought to
reduce the chance of differing expectations of im-
provement between groups at baseline. If the two
groups had differed in expectation of improvement
during the study, such a difference could have been
a confounding variable in the outcomes analyses”
Comment: The trial was referred to as single
blinded and study participants were blinded.How-
ever, it is unclear whether the unblinding of study
personnel would have introduced bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes assessors were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomized participants were accounted
Selective reporting (reporting bias) Low risk Trial registration not available, however, all pri-
mary and secondary outcomes specified in the
methods section were reported
Other bias Low risk No significant differences between groups at base-
line. No other apparent biases
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Candy 1995
Methods Study design: RCT
Setting: South Africa
Participants State of disease / disease type: Active / UC
Inclusion:Patients with activeUC, not undergone surgery for theirUC, andwere willing
to embark on a diet. Active disease was defined as the presence of diarrhoeal stools and/
or rectal bleeding
Exclusion: Systemic complications; on rectal or oral steroids in the past week
Age: Median 37 (Group 1) / 41 (Group 2)
Sex (M:F): 9:9
Disease location: Proctitis (4); Left-sided (10); Total colitis (4)
Medication use: Sulphasalazine (16)
Length of remission at study entry: n/a
Number randomized (n = 21): 11 (Group 1) / 10 (Group 2)
Number analyzed (n = 18): 11 (Group 1) / 7 (Group 2)
Post-randomisation exclusion (n = 3): 3 patients in Group 2 were found to have insuf-
ficient symptoms to warrant admission and were therefore excluded before intervention
Interventions Group 1: Diets which were systematically manipulated to exclude foods that appeared
to provoke symptoms. On day 1, all subjects were given a similar menu. A selection of
fruits, vegetables, grains, meat, and fish prepared by boiling, grilling, roasting, baking,
or microwave were included. Frying of food was prohibited. In the first week, only one
food item was allowed at breakfast and lunch. Supper comprised two foods. No food
was repeated more than once. No two foods of same type were allowed within a 48-hour
period. A brief summary of commonly available fruits and vegetables and their respective
“families”, based on botanical phylogenetic classification, was provided. Dairy products
were excluded from the first week’s diet but were introduced over the rest of the trial
period in the following order: skim milk, yoghourt, skim-milk cheese, full-cream milk,
cream and finally full cream cheeses. Permitted foods could be consumed ad libitum.
If hungry between meals, participants could only eat foods allocated to the previous or
next meal. The menu was expanded over 6 weeks to include a greater variety of foods
based on individual tolerance. Refined sugars, additives, preservatives, all condiments
and spices (other than salt) and drinks (other than boiled water) were prohibited. If/
when the participant became asymptomatic, the offending food was reintroduced. If
symptoms recurred upon reintroduction, the food was excluded for the remainder of the
trial
Group 2: No alteration to usual diet. All foods and drinks consumed were recorded
All participants: Patients were weighed, interviewed, and examined clinically at entry
to the study and weekly for 6 weeks
Outcomes Duration of follow-up: 6 weeks
1. Remission (defined as the passage of normal stools with absence of rectal bleeding)
2. Improvement (defined as a decrease in the number of diarrhoeal stools and/or a
diminution of rectal bleeding)
3. Sigmoidoscopy improvement
4. Biopsy improvement
Notes Funding source: Not stated
Conflict of interest: Not stated
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “They were randomized into either
diet (11) or control (10) subjects”
Comment: Participants were reportedly
randomized. However, no further details
were provided
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated. However, highly unlikely due
to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “Sigmoidoscopy was performed at
entry and completion on all subjects by one
of the investigators (J.P.W.) who was un-
aware of their status in the study ... each
sigmoidoscopic examination a biopsy was
taken and histological evaluation was sub-
sequently undertaken by a pathologist un-
aware of both the clinical and macroscopic
findings.” Comment: The outcome asses-
sors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attirition rate was low and balanced across
groups
Selective reporting (reporting bias) Low risk Trial registration/protocol not available.
However, outcomes specified in the meth-
ods section were reported
Other bias Low risk The controls had less severe disease than
the experimental group. However, the dif-
ference was not statistically significant. No
other apparent risk of biases
Dariel 2007
Methods Study design: RCT (Abstract)
Setting: Israel
Participants State of disease / disease type: Active / CD
Inclusion: Patients with mild CD (CDAI 150 - 250) not receiving corticosteroids and
on stable therapy for at least 4 weeks
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Dariel 2007 (Continued)
Exclusion: Not stated
Age: 36.1 ± 15
Sex (M:F): 24:27
Disease location: Not stated
Medication use: Not stated
Length of remission at study entry: Not applicable
Number randomized (n = 51): 32 (Group 1) / 19 (Group 2)
Number analyzed (n = 51): 32 (Group 1) / 19 (Group 2)
Post-randomisation exclusion (n = 12): 12 participants from Group 1 did not adhere
to the study protocol and complete the study
Interventions Group 1: Sequential elimination diets. Elimination diets for 30 food components were
prepared using a specially designed computer program
Group 2: Conventional nutritional advice
All participants: Not stated
Outcomes Duration of follow-up: 2 weeks period per each diet rotation (however, the number of
different diet rotations were not stated)
1. Remission (defined as CDAI < 150) and clinical improvement > 70 CDAI points)
2. IBDQ
Notes Funding source: Not stated
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “Patients were randomized (3:2) to
receive sequential elimination diets (32 pa-
tients) for 2-week periods for each diet rota-
tion or conventional nutritional advice (19
patients)”
Comment: Insufficient information pro-
vided
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Insufficient information provided. How-
ever, blinding of patients seems highly un-
likely due to the nature of intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided
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Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis seems to have been applied.
However the number of patients in remis-
sion is partially reported while IBDQ re-
ported per protocol. Very high attrition rate
only in Group 1 compared to Group 2 (12
vs 0)
Selective reporting (reporting bias) Unclear risk Study was published as an abstract, there-
fore not sufficiently reported to determine
whether all measured outcomes were re-
ported
Other bias Unclear risk Quote: “patients requiring a median of 5
different diet protocols per patient”
Comment:Diet protocols appeared to have
varied within Group 1. Insufficient infor-
mation provided to determine whether this
may have been a source of bias
Jones 1985
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Inactive / CD
Inclusion: Patients with active Crohn’s disease (CDAI >150) who entered remission
(CDAI < 150) after induction with parenteral nutrition or an elemental diet
Exclusion: Not stated
Age: 3 < 19 years and 17 between 19 to 49 years
Sex (M:F): 2:18
Disease location: Ileum (6); Terminal ileum (17); Colon (14); Rectum (2)
Medication use: None (5); Coirtcosteroids (14); Sulfasalazine (11); Azathioprine (2);
Antibiotics (3)
Length of remission at study entry: N/A
Number randomized (n = 20): 10 (Group 1) / 10 (Group 2)
Number analyzed (n = 20): 10 (Group 1) / 10 (Group 2)
Post-randomisation exclusion: None
Interventions Group 1: Investigated for specific food intolerances. Patients introduced a single food
each day, starting with those such as chicken and fish, leaving until later those such as
cereals and dairy products. A food that provoked symptoms was subsequently avoided.
During the first fortnight of food testing, an elemental diet was taken to maintain a
nutritionally adequate diet
Group 2: Unrefined carbohydrate fiber-rich diet
All participants: All patients were followed up in the outpatient clinic for 6 months and
by the dietitian as often as was thought necessary to give them adequate guidance and
encouragement in keeping to their diets
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Outcomes Duration of follow-up: 6 months
1. Relapse (CDAI > 150 were considered to be treatment failures)
2. Orosomucoid
3. ESR
Notes Funding source:not stated
Conflict of interest:not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “When patients entered remission
(CDAI <150) they were randomly allocated ei-
ther to take an unrefined carbohydrate fiber
rich (UCFR) diet or to be investigated for
specific food intolerances.”. Comment:insuffi-
cient information, It is unclear how the codes
were generated
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment
were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants not stated and is highly
unlikely due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “They were also seen separately every
month by R. J. D., who assessed the activity of
the disease without knowledge of the diet”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients assessed
Selective reporting (reporting bias) Unclear risk Trial registration not available and there was
insufficient information about the methods to
determine whether all outcomes were reported
Other bias Low risk Baseline characteristics similar, ERS higher in
IG albeit not statistically significant
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Keshteli 2016
Methods Study design: RCT (Abstract)
Setting: Canada
Participants State of disease / disease type: Inactive / UC
Inclusion: Adult UC patients in clinical remission (partial Mayo score ≤ 2) who had a
clinical relapse during the previous 18 months
Exclusion: Not stated
Age: 37.7 ± 15.0
Sex (M:F): 12:16
Disease location: Not stated
Medication use: Not stated
Length of remission at study entry: Not stated
Number randomized (n = 28): 14 (Group 1) / 14 (Group 2)
Number analyzed (n = 28): 14 (Group 1) / 14 (Group 2)
Post-randomisation exclusion: Not stated
Interventions Group 1: Alberta-based Anti-inflammatory Diet (anti-inflammatory diet designed to
increase patients’ intakes of probiotics, prebiotics, soluble fibers, and omega-3 polyun-
saturated fatty acids and decrease red meat intake)
Group 2: Diet based on Canada’s Food Guide
All participants: Dietary counselling
Outcomes Duration of follow-up: 6 months
1. Relapse (defined as partial Mayo of 3 or more)
2. CRP
3. SIBDQ
4. Fecal calprotectin
Notes Funding source: Not stated
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was referred to as an RCT, however,
no further details on random sequence gen-
eration were provided
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, however, it is unlikely that
blinding was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”All were assessed at baseline and at
month 6/or time of flare up
Comment: All participants appear to have
been accounted
Selective reporting (reporting bias) High risk All outcomes mentioned in the methods
section of the abstract were reported, al-
beit only partially reported as not signifi-
cant without further information
Other bias Unclear risk Insufficient information to determine
whether there were other sources of bias, as
study was published as an abstract
Levenstein 1985
Methods Study design: RCT
Setting:Inflammatory Bowel Disease Clinic, Italy
Participants State of disease / disease type: active and inactive randomized, only active analyzed /
CD
Inclusion:Patients with non-stenosingCDconsidered by their physicians to be following
a low residue diet as defined below
Exclusion:not stated
Age: mean 38.2 (Group 1) / 42 (Group 2) years
Sex (M:F): 36:24
Disease location: Ieocolitis - 17; Fistulas - 16; Extra-intestinal complications - 9
Medication use: Steroids - 27
Length of remission at study entry: not stated
Number randomized (n = 71): 36 (Group 1) / 35 (Group 2)
Number analyzed (n = 58): 30(Group 1) / 28 (Group 2)
Post-randomisation exclusion (n = 13): excluded after the first 3 months as free of ra-
diological/clinical evidence of recurrence after intestinal resection - 12; diagnosis change
- 1
Interventions Group 1: a low residue diet specifically forbidding legumes, whole grains, nuts, ordinary
juices (containing some pulp) and all fruits and vegetables with the exception of ripe
bananas and skinned potatoes.Patients were encouraged to buy a centrifuge in order to
prepare solid free extracts of fruits and vegetables
Group 2: gradually normalising Italian diet with a graded plan of gradual fiber reintro-
duction for patients previously following a low residue diet
All participants: Patients asked to eliminate any foods that proved to cause pain or
diarrhoea. Coffee, spices, simple sugars, alcohol, and dairy products were permitted
to patients in both groups as tolerated.Non-dietary medical and surgical therapy kept.
Multivitamin was prescribed by the research physician for patients in low residue diet
group. Patients were asked to discuss all questions concerning diet with the research
physician only
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Outcomes Duration of follow-up: approximately 24 months (range 23-34 months)
1. NCDAI (New CDAI)
2. Index developed by authors (5 point scale for pain, severity of diarrhoea, and global
assessment on how the patient has done since the start)
3. CDAI modified by Brest
4. Number of hospitalisations and surgeries required
5. Steroid therapy
Notes Funding source: not stated
Conflict of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Insufficient information on
how the random sequence was generated
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”Non-dietary medical and surgical
therapy, which was managed by two ’treat-
ing physicians’ (CP, CL) kept blind to the
diet assignment of each patient, was not af-
fected by the study“
Comment: Unclear whether bias was suffi-
ciently eliminated given that there was no
mention of participant blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote:”All outcome criteriawere evaluated
by the two ’blinded’ treating physicians,
who rated pain and diarrhoea on a five
point scale at each clinic visit“
Comment: All outcomes were blindly as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote ”All participants with active CD
were accounted for and those with inactive
CD were not analyzed due to lack of com-
pliance
Comment: However attrition rates were
balanced across groups
Selective reporting (reporting bias) Low risk All outcomes prespecified in the methods
section were reported
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Other bias Low risk Quote: “At randomisation, experimental
and control groups were virtually identical
in age, sex distribution, disease duration,
history of fistulae, NCDAI, and previous
adherence to a low residue diet”
Comment: Baseline characteristics were
balanced and there were no other apparent
biases
Lomer 2001
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Active / CD
Inclusion: Patients with active ileal or ileocolonic disease (CDAI >150) and were pre-
pared to accept full dietary advice and cease vitamin/mineral supplements
Exclusion: Patients were excluded if they were pregnant or lactating, or if they were
unable to understand written and verbal instructions
Age: 36.2 ± 11.8
Sex (M:F): 3:17
Disease location: Ileum only (6); Ileum and colon (14)
Medication use: Not stated
Length of remission at study entry: N/A
Number randomized (n = 20): 10 (Group 1) / 10 (Group 2)
Number analyzed (n = 18): 9 (Group 1) / 9 (Group 2)
Post-randomisation exclusion (n = 2): Lack of compliance (2). Two additional patients
only completed 3 of 4 months, but had the last value extended. One was withdrawn due
to gastrointestinal bleeding, iron deficiency anaemia, and unintentional weight loss of
9%, and another was lost to careful follow-up
Interventions Group 1: Diet low in microparticle (foods that could contain the dietary microparticle
titanium dioxide and aluminosilicates were excluded). Fibrous fruit and vegetables were
avoided. Toothpaste that did not contain titanium dioxide was recommended, while
filtered bottled water was supplied for all drinks, cooking, teeth cleaning, and washing
of fruits/vegetables. Fresh fruit and vegetables were peeled and washed (minimizing soil
contamination)
Group 2:Designed tomatch the trial diet, except that foods containing dietarymicropar-
ticle were not especially discouraged. Fibrous fruit and vegetables, which are known to
cause symptoms in stricturing Crohn’s disease, were excluded
All participants:Advice was given to achieve the dietary reference values for theUK adult
population. Dietary follow-up was always by the same dietitian, initially by telephone at
week 1, and then by interview at monthly intervals. Patients who were unable to comply
following the first follow-up interview at month 1 were excluded. At the end of the trial
all patients were encouraged to return to their usual diet. Prednisolone (up to 30 mg/
day), and in three patients (one trial, two controls) budesonide (up to 9 mg/day), were
prescribed as required according to normal clinical management, and their doses were
adjusted over the next few months with the aim of controlling symptoms while reducing
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Lomer 2001 (Continued)
corticosteroid usage. Aminosalicylates were given equally in 4 versus 4 participants. No
other anti-inflammatory or immunosuppressive drugs were given through the trial and
any other medication was monitored. The only other drugs used were loperamide and
ferrous sulphate in four and two different control patients, respectively
Outcomes Duration of follow-up: 4 months
1. Remission (defined as CDAI <150)
2. Corticosteroid use
Notes Funding source: NHS
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information
Allocation concealment (selection bias) Unclear risk Comment:Unclearwhether the envelopeswere
opaque and numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Other investigators and all patients
were blinded to the study randomization”
Comment: Unclear whether bias was suffi-
ciently eliminated given that the dieticianswere
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “Medical management was continued
routinely by clinicians unaware of the random-
ization.” and “Patients were also assessed, inde-
pendently of the dietitian, pre-treatment and
at monthly intervals, by a research nurse and
doctor unaware of the randomization.”
Comment: Outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low and balanced across
groups
Selective reporting (reporting bias) High risk All outcomes prespecified in the method sec-
tion were reported, however, outcome data
were reported as not significant (n.s) without
further information
Other bias High risk Quote: “At entry, the two groups were compa-
rable with respect to clinical history and demo-
graphic parameters, although the trial group
had a higher mean CDAI than the control
group (392 ±25 vs 302 ± 28; mean SEM; P <
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0.03)”
Comment: Participants in the intervention
group had higher CDAI scores
Lomer 2005
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Active / CD
Inclusion: Patients (18 - 70 years) with active Crohn’s disease of the ileum and/or colon
with a diagnosis confirmedby standard criteria according tohistological and/or radiologic
findings, with a current CDAI ≥ 150 and who could be treated as outpatients
Exclusion: Patients that had been treated within 3 months prior to recruitment (or had
concurrent treatment) with cyclosporine, methotrexate, azathioprine, mercaptopurine
or anti-tumour necrosis factor therapy. They were also excluded if they had external
fistulae or stoma; previous small bowel resection > 100 cm; previous colectomy or proc-
tocolectomy; isolated active peri-anal disease, proctitis or rectosigmoid disease; symp-
tomatic stenosis or strictures; taking part in another clinical trial; pregnancy or lactation
or planned pregnancy; unintentional weight loss > 10%bodyweight in the last 3months;
nutritional supplementation, such as enteral feeds or vitamin/mineral supplements that
could not be stopped
Age: 36 ± 13
Sex (M:F): 40:43
Disease location: Ileum only (30); Ileum and colon (28); Colon only (25)
Medication use: Not stated
Length of remission at study entry: N/A
Number randomized (n = 83): 22 (Group 1 - Low Calcium Low Microparticle) / 21
(Group 2 - Low Calcium Normal Microparticle) / 20 (Group 3 - Normal Calcium Low
Microparticle) / 20 (Group 4 - Normal Calcium Normal Microparticle)
Number analyzed (n = 83): 22 (Group 1) / 21 (Group 2) / 20 (Group 3) / 20 (Group
4)
Post-randomisation exclusion (n = 13):Dietary non-compliance (4); commencement
of azathioprine (3); Surgery (5); Error (1)
Interventions Group 1: Low calcium (400 mg/day) and low microparticle diet. Low microparticle
diets exclude foods that contain dietary microparticle (titanium dioxide and particulate
silicates). For more details, see characteristics of Lomer 2001
Group 2: Low calcium (400 mg/day) and normal microparticle diet. Based on a sham
manipulated diet that avoided a different group of food additives, namely sulphur dioxide
and the sulphites, which are preservatives used to prolong the shelf life of certain foods.
Typically, these included sausages and similar processed meats, dried fruits and shellfish.
Foods containing dietary microparticle were not discouraged. Bottled water was supplied
for all cold drinks, while it was recommended that tap water was used for cooking and
hot drinks such as tea and coffee. Titanium dioxide-free, but not particulate silicilate-
free toothpaste was provided. However, 5 mg/day of titanium dioxide was added back
into the diet with the supplement
Group 3: Normal calcium (800 mg/day) and low microparticle diet
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Group 4: Normal calcium (800 mg/day) and normal microparticle diet
All participants: Avoidance of fibrous fruits and vegetables, which can cause symptoms
in stricturing Crohn’s disease
At entry, prednisolone tablets, but not other corticosteroids, were prescribed for all
patients starting at 30 mg/day and the daily dose was reduced by 5 mg each week
to reach zero by week 6; patients receiving extra corticosteroids were then considered
failures in the primary analysis. Aminosalicylates which contain large particulate silicates
(mean diameter 10 mm) but not microparticle were prescribed according to normal
clinical practice and the dose was maintained throughout the intervention time. For
those patients taking a different aminosalicylate at entry, the prescription was changed to
Pentasa using dose equivalents. No other medication was allowed. All patients were also
advised on avoidance of fibrous fruit and vegetables and all received similarly detailed
written dietary information. Follow-up was initially by telephone at week 1, and then
by interview at weeks 4, 8, 12 and 16. Dietary compliance was monitored by dietary
recall and patients unable to comply following the first follow-up interview at week 4
were excluded. At the end of the intervention period (i.e., 16 weeks) all patients were
advised to return to their usual eating pattern with advice on meeting recommended
nutritional requirements (especially for calcium). Patients continued to be monitored by
their gastroenterologist at weeks 20, 28, 40 and 52
Outcomes Duration of follow-up: intervention 16 weeks (follow up weeks 16-52)
1. Clinical remission and response (remission defined as a CDAI <150, and clinical
response as a decrease in CDAI from baseline by ≥60 points)
2. Van Hees Index
3. IBDQ
4. ESR
5. CRP
6. Fecal calprotectin
7. Intestinal permeability
Notes Funding source: Not stated
Conflict of interest: Authors reported none conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were referred to only one di-
etitian (M.C.E.L.), who then randomly allo-
cated the patients to dietary treatment based
upon schemes given in independently sealed
envelopes in permuted blocks at each centre”
Allocation concealment (selection bias) Unclear risk Quote: “Patients were referred to only one di-
etitian (M.C.E.L.), who then randomly allo-
cated the patients to dietary treatment based
upon schemes given in independently sealed
envelopes in permuted blocks at each centre”
Comment: Unclear whether envelopes were
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opaque and numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Patients were not informed which di-
etary group they were in”
Comment: Apart from dietitian, all personnel
were blinded. However, it is unclear whether
bias was completely eliminated and remained
unbroken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients were seen by only one local
physician (gastroenterologist) throughout the
trial period who was blinded to the dietary
treatment” and “Patients were assessed inde-
pendently at pre-treatment and at weeks 4, 8,
12 and 16 by their physician who was unaware
of the study randomization”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analyses were based on intention to
treat, with no account taken of variations in
corticosteroid weaning. Missing data for pa-
tients who were withdrawn were extended to
the end of the 16 week treatment phase, but
not the follow-up phase, according to the last
value extended principle”
Selective reporting (reporting bias) Low risk All outcomes specified in the method section
were reported
Other bias Low risk “At entry all groupswere comparable for demo-
graphic parameters and there were no signifi-
cant differences between the groups for base-
line CDAI or distribution of Crohn’s disease”
Comment: Baseline characteristics were bal-
anced across groups and there were no other
apparent biases
Lorenz-Meyer 1996
Methods Study design: RCT
Setting: Germany
Participants State of disease / disease type: Inactive / CD
Inclusion: Patients with active Crohn’s disease (CDAI > 200) were considered for ad-
mission to the trial and were included once they reached remission (CDAI > 150) under
conventional steroid therapy over a 3-month period. Disease localization determined
within the last 2 years
Exclusion: Unwillingness to give written informed consent; questionable ability to co-
operate; concomitant intake of salicylates or nonsteroidal antiphlogistics; intake of drugs
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commonly used for treatment of Crohn’s disease, such as metronidazole, azathioprine,
5-aminosalicylic acid, sulfasalazine, total parenteral nutrition, and elemental diet; short
bowel syndrome; proven steatorrhea; pregnancy
Age: 30.7 ± 10.3
Sex (M:F): 67:135
Disease location: Small bowel (31); Large bowel (35); Both (136)
Medication use: Not stated
Length of remission at study entry: Not stated
Number randomized (n = 204): 69 (Group 1) / 70 (Group 2) / 65 (Group 3)
Number analyzed (n = 202): 69 (Group 1) / 70 (Group 2) / 63 (Group 3)
Post-randomisation exclusion (n = 2): No baseline data due to non-compliance im-
mediately after randomisation (2)
Interventions Group 1 (Diet): Patients in the diet group were instructed to adhere to a low-carbohy-
drate diet of less than 84 g/day
Group 2 (Verum):Verum consisted of two gelatine capsules three times a day containing
1 g of an ethylester fish oil concentrate with 55% eicosapentanoic acid (C20:5n3) and
30% docosahexanoic acid (C22:6n3) as their major omega-3 fatty acid components. Pa-
tients were to follow general nutrition guidelines from the German Society of Nutrition.
Most carbohydrates were to be ingested in a fiber-rich form
Group 3 (Placebo):Placebo capsules (two, three times a day) contained the same amount
of corn oil as the Group 2 verum. Double-blind conditions were intended for the verum-
placebo comparisonPatientswere to followgeneral nutrition guidelines from theGerman
Society of Nutrition. Most carbohydrates were to be ingested in a fiber-rich form
All participants: During the first 7 weeks all patients were treated daily with 8 mg
methylprednisolone. During the 8th week steroids were tapered to 6, 4, 2, and, finally,
0 mg/day.Patients were urged to seek the investigator’s immediate advice in case of
substantial deterioration of their state of health
Outcomes Duration of follow-up:12 months
1. Relapse (increase of the CDAI above 200 points and by at least 60 points above base
line plus an increase of CRP serum level two standard deviations above the mean of the
healthy population)
Notes Funding source: not stated
Conflict of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization
Allocation concealment (selection bias) Unclear risk Quote: “block size blinded to the centers”
Comment: Insufficient information on allo-
cation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blind conditions were in-
tended for the verum-placebo comparison”
Comment: Patients received placebo pills. We
assume the placebo was identical to the active
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “The intention-to-treat approach was
chosen as the essential method of inference.”
and “Dropouts andwithdrawalswere prospec-
tively documented in the Case Report Forms”
Coimment: Low attrition rates and reasons
were balanced across groups
Selective reporting (reporting bias) Unclear risk All outcomes appear to have been reported
except CRP data which was measured as part
of the definition for relapse. Trial registration
not available to confirm whether CRP was an
outcome of interest
Other bias Low risk Quote: “The three randomized groups were
comparable on the basis of age, sex, Broca in-
dex, body mass index (BMI), duration,and lo-
calization of disease, indices of active phases,
peakCDAI before entry, CDAI at entry, num-
bers of external fistulas, and registrations of a
palpable abdominal mass; no noticeable dif-
ference in laboratory findings at study entry
(confirmed by chi-square tests, H-tests, and
analyses of variance not showing any extreme
P values.”
Comment: Similar baseline characteristics
and no additional sources of bias were identi-
fied
Mutlu 2016
Methods Study design: RCT (Abstract)
Setting: USA
Participants State of disease / disease type: Inactive / CD
Inclusion: Subjects with quiescent CD, with medical induction of remission from two
sites located in Illinois and Georgia
Exclusion: Not stated
Age: 45 ± 14.5 years
Sex (M:F): 21:33
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Disease location: Not stated
Medication use: Not stated
Length of remission at study entry: Not stated
Number randomized (n = 54): 16 (Group 1) / 19 (Group 2) / 19 (Group 3)
Number analyzed: Not stated
Post-randomisation exclusion: Not stated
Interventions Group 1: Anti-IBD diet and placebo supplement
Group 2: Fructooligosaccharide supplement and ’placebo diet’
Group 3: ’Placebo diet’ and placebo supplement
All participants:The subjects were followed until either they had a flare or up to 12
months. Biopsy samples were collected from the sigmoid colon before and after the study
interventions, and were analyzed for bacterial composition
Outcomes Duration of follow-up: 12 months
1. Relapse (defined as the need for a new medication for treatment or a 100-point rise
in the CDAI)
2. Biopsy (colon)
3. Microbiome
Notes Funding source: Not reported
Conflict of interest: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were reportedly randomized to
three study groups. However, it is unclear
how this was done
Allocation concealment (selection bias) Unclear risk The methods used for allocation conceal-
ment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “In a randomized, placebo-con-
trolled, double-blinded study, we enrolled
54 subjects with quiescent CD”
Comment: The study appears to be double
blinded. Whilst there is insufficient infor-
mation to make a judgement, the review
authors consider this adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “In a randomized, placebo-con-
trolled, double-blinded study, we enrolled
54 subjects with quiescent CD...”
Comment: The study appears to be double
blinded. Whilst there is insufficient infor-
mation to make a judgement, the review
authors consider this adequate
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants appear to have been ac-
counted for
Selective reporting (reporting bias) Unclear risk The study was published as an abstract
with insufficient information to determine
whether there was selective reporting
Other bias Unclear risk Quote: “The study groups were not differ-
ent in regards to age (mean = 45 ± 14.5
years), gender (F/M=33/21), race, or edu-
cation”
Comment: There was no information re-
garding other baseline characteristics
Riordan 1993
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Inactive / CD
Inclusion: Patients with active CD confirmed by standard radiological and histological
tests within 2 months of entry; HBI > 6; permanent residents of the health districts
where the hospitals were situated Patients who achieved remission with an elemental diet
were then included in the trial
Exclusion: Pregnancy, lactation, surgical complications (such as intestinal obstruction,
abscesses, and symptomatic fistulae), and severe complications necessitating corticos-
teroids, such as uveitis Patients with CD of the rectum only were excluded, as were those
with perianal disease more severe than simple fissures or skin tags
Age: 33.7 ± 12.2
Sex (M:F): 26:52
Disease location: Small bowel (31); Large bowel (21); Small and large bowel (26)
Medication use: Azathioprine (5)
Length of remission at study entry: Not stated
Number randomized (n = 78): 40 (Group 1) / 38 (Group 2)
Number analyzed (n = 78): 40 (Group 1) / 38 (Group 2)
Post-randomisation exclusion (n = 14): Non-compliance (7); Intercurrent illness (3);
Steroid side-effects (diabetes mellitus and severe furunculosis) (2); Pregnancy (2)
Interventions Group 1: Elemental diet with instruction to reintroduce a single food each day and to
exclude any food that provoked symptoms such as diarrhoea and pain. They were also
given placebo tablets identical to the prednisolone and instructed to reduce the dose in
the same way
Group 2: Prednisolone 40 mg/day. If they remained in remission, the prednisolone dose
was reduced to 30 mg after 1 week, to 20mg after 1month, and to 10mg after 2months,
and withdrawn after 3 months. They received general dietary advice from a dietitian
All participants: Both groups saw the dietitians at every clinic visit and were free to
telephone for advice if necessary. Patients in both groups were told that they had entered
a trial of diet in CD and that the tablets might be corticosteroids or a harmless placebo
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Outcomes Duration of follow-up: 24 months or until relapse
1. Relapse / Failure (HBI > 6 was taken as a relapse. Other criteria for treatment failure
included: unwillingness by the patient to continue; a diet found on computer analysis
to be deficient in energy, protein, or any other nutrient that could not be replaced by
simple supplements; surgery for CD; serious medical complications; and steroid side-
effects severe enough to warrant withdrawal of therapy
2. ESR
3. CRP
Notes Funding source: Not stated
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomisation codes were separate
for each participating centre and were stratified
for the extent of the disease”
Comment: Authors did not indicate how the
randomisation codes were generated
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment
were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients in both groups were told that
they had entered a trial of diet in CD and that
the tablets might be corticosteroids or a harm-
less placebo [...] The group assignment was
known to the dietitians who advised the pa-
tients but not to the physicians who assessed
their progress”
Comment: The intervention diet and corticos-
teroid groups received placebo tablets and gen-
eral (dummy) dietary advice respectively
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The group assignment was known to
the dietitians who advised the patients but not
to the physicians who assessed their progress”
Comment: The outcomes assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low and reasons were bal-
anced across groups
Selective reporting (reporting bias) High risk Trial registration not available, however, out-
come results were described as not statistically
significant without providing any data
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Other bias Low risk Quote: “there were no differences in these vari-
ables between the 38 patients assigned corticos-
teroid treatment and the 40 patients assigned
diet treatment”
Comment: Baseline characteristics were bal-
anced across groups and there were no other
apparent biases
Ritchie 1987
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Inactive / CD
Inclusion: Patients with Crohn’s disease who were well, either with known structural
disease or after resection of all apparently diseased intestine, and who were receiving
no treatment other than nutritional supplements, antidiarrhoeal drugs, or maintenance
sulphasalazine
Exclusion: Patients with a stoma and those with disease limited to the stomach or
duodenum, or both, were excluded, as were patients with anal disease only
Age: 14.4 - 77.7 years
Sex (M:F): 130:222
Disease location: Small bowel (68); Small and large bowel (37); Large bowel (55); No
macroscopic disease after resection (134)
Medication use: Sulphasalazine (64)
Length of remission at study entry: Not stated
Number randomized (n = 352): 190 (Group 1) / 162 (Group 2)
Number analyzed (n = 352): 190 (Group 1) / 162 (Group 2)
Post-randomisation exclusion (n = 56):Non-compliance (24); Unknown (14); Unre-
lated (18)
Interventions Group 1: Advised to eat carbohydrate in its natural unrefined state only, avoiding all
products containing sugar or white flour
Group 2: Diet with carbohydrate in its refined form (e.g. white flour and rice) and
avoiding unrefined carbohydrate foods. Sugar intake was unrestricted
All participants: Both types of diets were accompanied by a booklet; patients given a
list of ”acceptable“ and ”unacceptable“ foods. At every visit the dietitian reviewed the
patient’s diet and strongly reinforced the advice given
Outcomes Duration of follow-up: 24 months
1. Clinical deterioration (defined as the need for surgical or medical treatment in hos-
pital; need for corticosteroid, sulphasalazine [if not already being taken], antibiotic, or
immunosuppressive drug treatment for intestinal disease as an outpatient; or as a wors-
ening of symptoms attributable to the disease and severe enough to warrant withdrawal
from the trial)
2. Wellbeing at end of the trial was assessed in terms of symptoms, body weight, and
laboratory findings
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Notes Funding source: Not stated
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”were referred to the dietitian, who held
the randomization code as a consecutive series
of sealed envelopes”
Comment: It is unclear how the codes were
generated
Allocation concealment (selection bias) Unclear risk Quote: “were referred to the dietitian, who held
the randomization code as a consecutive series
of sealed envelopes”
Comment: It is unclear whether the envelopes
were opaque and numbered
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “A further explanation of the principles
of each diet was given by the dietician, and if
the patient agreed to accept whichever of the
two diets was allocated the next envelope was
opened and the trial diet disclosed. The clini-
cian was not informed of the diet allocated and,
as far as possible, remained blind to the advice
given”
Comment: Blinding appears to have been bro-
ken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”A further explanation of the principles
of each diet was given by the dietitian, and if
the patient agreed to accept whichever of the
two diets was allocated the next envelope was
opened and the trial diet disclosed. The clini-
cian was not informed of the diet allocated and,
as far as possible, remained blind to the advice
given”
Comment: Clinician was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates were high(30%) and generally
balanced across groups, however, there were
more withdrawals from the unrefined carbohy-
drate group due to non-compliance compared
to the refined carbohydrate group (10.5% ver-
sus 2.5%)
64Dietary interventions for induction and maintenance of remission in inflammatory bowel disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ritchie 1987 (Continued)
Selective reporting (reporting bias) High risk Data on outcomes related to clinical improve-
ment were collected and described as showing
no significant change without full reporting of
data
Other bias Low risk Baseline characteristics were balanced. No
other apparent biases
Strisciuglio 2013
Methods Study design: RCT
Setting: Italy
Participants State of disease / disease type: Active / UC
Inclusion: Children with newly diagnosed UC
Exclusion: Children who had received therapy-inducing remission of UC and/or chil-
dren who required surgery for complications related to UC
Age: Mean 11.2 (range 4.6 - 17) years
Sex (M:F): 14:15
Disease location: Proctosigmoiditis (7); Left-sided colitis (3); Extensive colitis (6); Pan-
colitis (13)
Medication use: Steroid therapy (16)
Length of remission at study entry: N/A
Number randomized (n = 29): 14 (Group 1) / 15 (Group 2)
Number analyzed (n = 29): 14 (Group 1) / 15 (Group 2)
Post-randomisation exclusion: None
Interventions Group 1: Cow’s milk protein elimination diet
Group 2: Usual diet
All participants: Patients with PUCAI score ≥ 35 received concomitant steroid in-
duction treatment (oral methylprednisolone: 1 mg/kg/day, maximum 40 mg/day per 4
weeks) and oral mesalazine induction and mesalazine maintenance treatment (50 mg/
kg/day), while subjects with a PUCAI score < 35 received exclusively oral mesalazine
induction and mesalazine maintenance treatment (50 mg/kg/day). All children received
supplemental elemental calcium 1000 mg/day and vitamin D3 0.25 mcg/day for 1 year.
After 4 weeks, patients who were in remission began tapering off corticosteroids on a
weekly basis on the basis of the PUCAI score. Upon induction of remission patients
continued to received concomitant therapy for 1 year or until relapse. Parents and/or
patients recorded in a daily diary only the amount and type of not allowed food. Available
to contact investigator whenever needed. When a relapse occurred, the study protocol
was stopped and the patient was treated according to the physician’s preference
Outcomes Duration of follow-up: 12 months
1. Remission (Clinical remission was defined on the basis of PUCAI < 10, while clinical
response to the induction treatment was identified as a PUCAI score a change of at least
20 points from baseline
2. Relapse (occurrence or worsening of symptoms accompanied by an increase of PUCAI
>10 points, sufficient to require rescue treatment with corticosteroids, azathioprine/
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immunosuppressive agents, or surgery)
3. ESR
4. CRP
5. Fecal Calprotectin
Notes Funding source:not stated
Conflict of interest:not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Assignment to CMP elimination diet or
free diet was determined according to a computer-
generated randomization scheme”
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment were
not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The paediatric gastroenterologists (AS;
EM) made all decisions regarding induction ther-
apeutic intervention being unaware of diet group
allocation”
Comment: However, blinding of the participants
or caregivers (parents) is unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All histologic specimens were reviewed
under code by a single pathologist experienced in
analysing paediatric intestinal biopsies, blinded to
the patients’ clinical details, who scored biopsies
according to the Matts’ histologic criteria”
Comment: Assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk The only withdrawals which occurred were due to
relapse. All participants were accounted for
Selective reporting (reporting bias) Low risk Trial registration not available, however, all out-
comes appear to have been reported
Other bias Low risk Patients were similar at baseline. There were no
other apparent biases
66Dietary interventions for induction and maintenance of remission in inflammatory bowel disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wright 1965
Methods Study design: RCT
Setting: England
Participants State of disease / disease type: Active / UC
Inclusion: All patients seen during an attack of UC confirmed by sigmoidoscopy and
barium enema examination, prepared to keep to a strict diet for a period of one year and
to attend for follow-up at monthly intervals, not on corticosteroids for the attack for
more than one week, and have no major complication of UC
Exclusion: See Inclusion Criteria
Age: Not stated
Sex: Not stated
Disease location: Not stated
Medication use: Not stated
Length of remission at study entry: N/A
Number randomized (n = 77): 26 (Group 1) / 27 (Group 2) / 24 (Group 3)
Number analyzed (n = 50): 26 (Group 1) / 0 (Group 2) / 24 (Group 3)
Post-randomisation exclusion: All 27 participants in Group 2 were excluded due to
poor adherence and inadvertent introductionofmilk protein in some brands ofmargarine
and some articles of gluten-free diet
Interventions Group 1: Milk-free, low-roughage diet excluded all milk/products (fresh milk, cheese,
or powdered milk). Butter was permitted
Group 2: Gluten-free plus milk-free diet. Butter was not permitted and patients were
told to use margarine instead
Group 3: Exclude a variety of items of diet, such as fried foods, condiments, and ice
cream, but constituents of these foods which might be antigenic were included in the
list of other foods which were permitted. In particular, they were advised to consume
milk and milk products liberally
All participants: A diet sheet was prepared for each of the diets and patients were
referred to a dietitian for detailed explanation. Prednisolone by mouth in a dose of 5
mg six-hourly for six weeks and hydrocortisone hemisuccinate 100 mg nightly by rectal
infusion for two months, together with any general medical measures necessary for the
particular case. If the attack was severe enough to warrant admission to hospital the
dose of prednisolone was doubled and the rectal infusion used twice daily. All patients
were given two tablets of Omnivite Forte for the period of the trial. A similar course of
treatment was given for each relapse
Outcomes Duration of follow-up: 12 months
1. Relapse (defined as diarrhoea with an average of four or more stools a day for at least
a week and with macroscopic blood present, together with sigmoidoscopic evidence of
diffuse inflammation)
2. Treatment failure (based on (a) the attack continued to be severe and required either
surgical treatment or treatment with systemic corticosteroids for more than six weeks;
or (b) three successive relapses, in addition to the initial attack during the trial period)
3. ESR
Notes Funding source: Not stated
Conflict of interest: Not stated
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients presenting with an attack of
ulcerative colitis were allocated at random to
one of three dietary groups […] patients in
each of these clinical categories were allotted at
random to the dietary groups, employing re-
stricted randomization to keep the numbers in
the three dietary groups approximately equal”
Comment: There was no mention of random
sequence generation
Allocation concealment (selection bias) Unclear risk The methods used for allocation concealment
were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Dummy diet used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk All 27 participants randomized to one of the
three trial arms were excluded from the analysis
Selective reporting (reporting bias) High risk Quote: “The immunological findings are only
mentioned briefly, as they are being reported
in detail separately (Wright and Truelove, 1965
Circulating Antibodies to Dietary Proteins in
Ulcerative Colitis; British Medical Journal 2:
142-144)”
Comment: Upon checking the named study,
it was discovered that no secondary outcome
(ESR, hemoglobin) was reported
Other bias Unclear risk Insufficient information reported to make
judgement on other sources of bias
Abbreviations: BMI: body mass index; CD: Crohn’s disease; CDAI: Crohn’s Disease Activity Index; CRP: C-reactive protein; ESR:
erythrocyte sedimentation rate; F: female; HBI: Harvey-Bradshaw Index; IBDQ: Inflammatory Bowel Disease Questionnaire; M:
male; MRI: magnetic resonance imaging; N/A: not applicable or available; pHBI: Partial Harvey-Bradshaw Index; PUCAI: Pediatric
Ulcerative Colitis Activity Index; RCT: randomized controlled trial; SCCAI: Simple Clinical Colitis Activity Index; SIBDQ: Short
Inflammatory Bowel Disease Questionnaire; TNF: tumor necrosis factor; UC: ulcerative colitis; USA: United States of America
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barnes 2016 Not a randomized controlled trial
Beattie 1994 Not a study. Editorial on Riordan 1993
Bentz 2010 Separate results were not reported for participants with active and inactive Crohn’s disease. Outcomes of
interest were not evaluated
Boneh 2017 Study compared interventions involving enteral nutrition
Brandes 1982 Not a randomized controlled trial
Castro 1995 Review article. Not a study
Ciccimarra 1998 Review article. Not a study
Cohen 2012 Not a randomized controlled trial
Davies 1978 Not a randomized controlled trial
Dunn 2017 Study primarily compared oral nutrition supplements
El-Tahir 1998 Intervention was a dietary supplement: omega-3 fatty acids
Gunasekeera 2016 Separate results were not reported for participants with active and inactive Crohn’s disease
Halmos 2016 Not a randomized controlled trial
Kyaw 2014 Disease activity (active or inactive ulcerative colitis) at baseline was not reported and unknown
Mikolaitis 2013 Outcomes of interest were not evaluated
NCT01749813 Study terminated with no results
NCT02093780 Authors contacted on 28/01/2018 without response. Likely ClinicalTrails.gov entry of Keshteli 2016
NCT02213835 Authors contacted on 28/01/2018 without response
NCT02231814 Study compared interventions involving enteral nutrition
NCT02345733 Not a randomized controlled trial
NCT02357537 Authors contacted on 24/01/2018 without response
NCT02426567 Authors contacted. Trial involves healthy individuals
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(Continued)
NCT02469220 Outcomes of interest were not evaluated
NCT02610101 Authors contacted on 28/01/2018 without response
NCT02922881 Not a randomized controlled trial
NCT02930564 Authors contacted on 28/01/2018 without response
NCT02945488 Study abandoned
NCT03171246 Not a randomized controlled trial
Pedersen 2014 Separate results were not reported for participants with active and inactive Crohn’s disease. Separate results
were not reported for participants with active and inactive ulcerative colitis
Pedersen 2017 Separate results were not reported for participants with active and inactive Crohn’s disease. Separate results
were not reported for participants with active and inactive ulcerative colitis
Pituch-Zdanowska 2018 Not a randomized controlled trial
Stange 1990 Separate results were not reported for participants with active and inactive Crohn’s disease
Strohm 1981 Study compared interventions involving enteral nutrition
Svolos 2016 Outcomes of interest were not evaluated
Vincenzi 2016 The study made no reference to our population of interest (Crohn’s disease or ulcerative colitis)
Characteristics of studies awaiting assessment [ordered by study ID]
Bodini 2018
Methods Randomized controlled trial
Participants Participants with IBD including UC and CD
Interventions Low FODMAP versus normal FODMAP diet for 6 weeks
Outcomes Disease activity (Mayo score for UC and Harvey Bradshaw Index for CD)
Quality of life (IBDQ)
Adherence to diet
Fecal calprotectin
Notes
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Tapete 2018
Methods Randomized controlled trial
Participants Participants with IBD (UC or CD) in remission but without complete control of intestinal symptoms
Interventions Low FODMAP versus standard of care diet for 6 to 8 weeks
Outcomes Intestinal, general or emotional symptoms (questionnaires), quality of life (IBDQ) and VAS to characterize the
intestinal symptoms before and after diet
Notes
IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; FODMAP: fermentable Oligosaccharides, disaccharides,
monosaccharides and polyols; IBDQ: Inflammatory Bowel Disease Questionnaire; VAS: visual analogue scale
Characteristics of ongoing studies [ordered by study ID]
NCT02825316
Trial name or title Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn’s Disease
Methods Randomized, parallel assignment, double blinded controlled trial
Participants Estimated enrollment: 100 participants, 18-75 years, both sexes, active CD (Montreal classification: B1);
Induction therapy with corticosteroids, 5-ASA, azathioprine, 6-mercaptopurine, methotrexate, or biologic
therapy
Interventions 8 weeks Mediterranean Diet versus 8 weeks Low Residue Diet
Outcomes Primary: CDAI; C-reactive protein; Calprotectin; Remission rate- CDAI < 150 + normal CRP / fecal cal-
protectin; Response rate- decrease in 70 points in CDAI + decreased CRP / fecal calprotectin; Microbial
composition
Starting date July 2016
Contact information Lihi Godny, Tel-Aviv Sourasky Medical Center
Notes
NCT02858557
Trial name or title The Effect of the Mediterranean Diet and the Specific Carbohydrate Diet on Microbial Profile and Disease
Outcomes in Patients With Inflammatory Bowel Diseases
Methods Randomized, crossover, double blinded clinical trial
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NCT02858557 (Continued)
Participants Estimated enrollment: 70 participants, 18-70 years, both sexes, patients with pouch surgery because of
refractory UC or Familial Adenomatous Polyposis and have a functioning pouch
Interventions 7 days of Mediterranean diet with cross over to 7 days of specific carbohydrate diet vs 7 days of specific
carbohydrate diet with cross over to 7 days of Mediterranean diet
Outcomes Primary: Microbial diversity (Shannon α-diversity index);Secondary: PDAI, CRP, fecal calprotectin, IBDQ,
Microbial composition
Starting date September 2016
Contact information Lihi Godny, Tel-Aviv Sourasky Medical Center
Notes
NCT03012542
Trial name or title Randomized Trial of Diet for Crohn’s Disease and Impact on Disease Activity and the Microbiome
Methods Randomized, parallel assignment, quadruple masking, controlled trial
Participants Estimated enrollment: 32 participants, 18 years and older, active CD, both sexes,fecal calprotectin ≥ 300,
mild to moderate disease activity based upon a Harvey Bradshaw Index of 5 to 16 and on stable medication
doses for ≥ 2 months
Interventions Diet controlled in amount and source of carbohydrates or fiber containing foods versus Diet controlled in
amount and source of carbohydrates or fiber containing foods
Outcomes Primary: fecal calprotectin remission; Secondary: fecal calprotectin response, clinical response, metagenomics,
microbiota correlation with clinical disease activity and inflammatory biomarkers, future use
Starting date January 2017
Contact information Timothy L Zisman, MD, MPH, University of Washington Medical Center
Notes
NCT03053713
Trial name or title The Effect of Diet Modification on Clinical Disease Activity, the Gut Microbiome and Immune Responses
in Patients With Ulcerative Colitis
Methods Randomized,parallel assignment, open label clinical trial
Participants Estimated enrollment: 102 participants , 18 to 64 years, UC in remission, on oral 5-ASA, methotrexate,
azathioprine, or 6-mecaptopurine with no changes in dosage for 2 months prior to the start of the study
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NCT03053713 (Continued)
Interventions Mediterranean diet pattern vs Habitual diet
Outcomes Primary: SCCAI; Secondary: SIBDQ, fecal microbiota, fecal calprotectin, CRP, serum ferritin,
Starting date April 4, 2017
Contact information Deanna L Gibson, PhD, University of British Columbia - Okanagan
Notes
NCT03058679
Trial name or title Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and
Mediterranean Diets to Induce Remission in Patients With Crohn’s Disease
Methods Randomized,parallel assignment, open label clinical trial
Participants Estimated enrollment: 194 participants, 18 years and older, both sexes, active CD (sCDAI score >175), active
inflammation documented by a fecal calprotectin concentration > 250 ug/g or high sensitivity C-reactive
protein (hs-CRP) > 5 mg/L measured at screening, able to receive weekly food shipments delivered every
Friday for 6 weeks
Interventions Specific Carbohydrate Diet vs Mediterranean Style Diet (all food provided)
Outcomes Primary: Symptomatic remission (sCDAI), reduction in bowel inflammation (calprotectin < 250 mcg/gm
and > 50% reduction from baseline); Secondary: clinical remission (Harvey Bradshaw Index, reduction in
systemic inflammation (hsCRP < 5mg/L > 50% reduction from baseline)
Starting date September 29, 2017
Contact information James D Lewis, MD, MSCE, University of Pennsylvania
Notes
Abbreviations: 5-ASA, 5-aminosalicylate; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; hs-CRP, high sensitivity C-reactive protein; IBDQ, Inflammatory Bowel Disease Questionnaire;
PDAI, Pouchitis Disease Activity Index; SCCAI, Simple Clinical Colitis Activity Index; sCDAI, Short Crohn’s Disease Activity
Index; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; UC, ulcerative colitis
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D A T A A N D A N A L Y S E S
Comparison 1. Intervention diet versus control diet in active Crohn’s disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Induction of remission 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 High-fiber, low refined
carbohydrates diet
1 7 Risk Ratio (M-H, Random, 95% CI) 7.20 [0.53, 97.83]
1.2 Low microparticle diet 2 103 Risk Ratio (M-H, Random, 95% CI) 3.13 [0.22, 43.84]
1.3 Symptoms-guided diet 1 51 Risk Ratio (M-H, Random, 95% CI) 20.00 [1.27, 315.40]
1.4 Highly restricted, organic
diet
1 18 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.39, 2.53]
1.5 Low calcium diet 1 83 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.67, 2.29]
2 Surrogate inflammatory
biomarker - CRP
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Highly restricted, organic
diet
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Surrogate inflammatory
biomarker - ESR
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Highly restricted, organic
diet
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Endoscopic improvement 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Highly restricted, organic
diet
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Health related quality of life -
IBDQ
2 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Symptoms-guided diet 1 51 Mean Difference (IV, Random, 95% CI) 23.75 [7.12, 40.38]
5.2 Highly restricted, organic
diet
1 14 Mean Difference (IV, Random, 95% CI) 4.0 [-17.86, 25.86]
6 Need for surgery 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Low microparticle diet 1 20 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.14, 65.90]
6.2 Low fiber diet 1 58 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.35, 3.91]
7 Disease progression 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Highly restricted, organic
diet
1 14 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.08, 4.35]
7.2 Low fiber diet 1 58 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.61, 2.72]
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Comparison 2. Intervention diet versus control diet in inactive Crohn’s disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Low refined carbohydrate
diet
3 567 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.87, 1.25]
1.2 Symptoms-guided diet 2 98 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.28, 1.01]
1.3 Low red, processed meat
diet
1 214 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.85, 1.26]
1.4 Exclusion diets (low
disaccharides, grains, saturated
fats, red and processed meats)
1 54 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 1.76]
2 Surrogate inflammatory
biomarker - CRP
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Symptoms-guided diet 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Surrogate inflammatory
biomarker - ESR
2 95 Mean Difference (IV, Random, 95% CI) -7.29 [-17.22, 2.64]
3.1 Symptoms-guided diet 2 95 Mean Difference (IV, Random, 95% CI) -7.29 [-17.22, 2.64]
4 Need for surgery 2 372 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.19, 1.00]
4.1 Low refined carbohydrate
diet
2 372 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.19, 1.00]
5 Disease progression 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Low refined carbohydrate
diet
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Escalation of therapy 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Low refined carbohydrate
diet
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Symptoms-guided diet 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Intervention diet versus control diet in active ulcerative colitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Induction of remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Symptoms-guided diet 1 21 Risk Ratio (M-H, Random, 95% CI) 8.25 [0.50, 136.33]
2 Clinical improvement 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Symptoms-guided diet 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Endoscopic improvement 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Symptoms-guided diet 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Histologic improvement 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Symptoms-guided diet 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. Intervention diet versus control diet in inactive ulcerative colitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Anti-inflammatory diet
(Alberta-based)
1 28 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.42, 3.70]
1.2 Carrageenan-free diet 1 15 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.15, 1.64]
1.3 Milk free diet 2 77 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.60, 1.15]
2 Fecal calprotectin 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Carrageenan-free diet 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Surrogate inflammatory
biomarker - TNF-α
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Carrageenan-free diet 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Surrogate inflammatory
biomarker - IL-6
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Carrageenan-free diet 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Surrogate inflammatory
biomarker - IL-8
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Carrageenan-free diet 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Health related quality of life -
SIBDQ
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Carrageenan-free diet 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 1
Induction of remission.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 1 Induction of remission
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-fiber, low refined carbohydrates diet
Brotherton 2014 4/4 0/3 100.0 % 7.20 [ 0.53, 97.83 ]
Subtotal (95% CI) 4 3 100.0 % 7.20 [ 0.53, 97.83 ]
Total events: 4 (Intervention diet), 0 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Low microparticle diet
Lomer 2001 7/10 0/10 37.9 % 15.00 [ 0.97, 231.84 ]
Lomer 2005 16/42 13/41 62.1 % 1.20 [ 0.66, 2.17 ]
Subtotal (95% CI) 52 51 100.0 % 3.13 [ 0.22, 43.84 ]
Total events: 23 (Intervention diet), 13 (Control diet)
Heterogeneity: Tau2 = 2.83; Chi2 = 3.77, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.85 (P = 0.40)
3 Symptoms-guided diet
Dariel 2007 16/32 0/19 100.0 % 20.00 [ 1.27, 315.40 ]
Subtotal (95% CI) 32 19 100.0 % 20.00 [ 1.27, 315.40 ]
Total events: 16 (Intervention diet), 0 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
4 Highly restricted, organic diet
Bartel 2008 4/8 5/10 100.0 % 1.00 [ 0.39, 2.53 ]
Subtotal (95% CI) 8 10 100.0 % 1.00 [ 0.39, 2.53 ]
Total events: 4 (Intervention diet), 5 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Low calcium diet
Lomer 2005 16/43 12/40 100.0 % 1.24 [ 0.67, 2.29 ]
Subtotal (95% CI) 43 40 100.0 % 1.24 [ 0.67, 2.29 ]
Total events: 16 (Intervention diet), 12 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 6.09, df = 4 (P = 0.19), I2 =34%
0.01 0.1 1 10 100
Favours control diet Favours intervention diet
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Analysis 1.2. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 2
Surrogate inflammatory biomarker - CRP.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 2 Surrogate inflammatory biomarker - CRP
Study or subgroup Exclusion diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Highly restricted, organic diet
Bartel 2008 5 1.1 (1) 9 0.7 (0.4) 0.40 [ -0.51, 1.31 ]
-10 -5 0 5 10
Favours exclusion diet Favours control diet
Analysis 1.3. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 3
Surrogate inflammatory biomarker - ESR.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 3 Surrogate inflammatory biomarker - ESR
Study or subgroup Experimental diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Highly restricted, organic diet
Bartel 2008 5 15 (3) 9 20 (15) -5.00 [ -15.15, 5.15 ]
-20 -10 0 10 20
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 4
Endoscopic improvement.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 4 Endoscopic improvement
Study or subgroup Experimental diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Highly restricted, organic diet
Bartel 2008 3/5 1/9 5.40 [ 0.74, 39.17 ]
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
Analysis 1.5. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 5
Health related quality of life - IBDQ.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 5 Health related quality of life - IBDQ
Study or subgroup Intervention diet Control diet
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Symptoms-guided diet
Dariel 2007 32 175.9 (28.8) 19 152.15 (29.6) 100.0 % 23.75 [ 7.12, 40.38 ]
Subtotal (95% CI) 32 19 100.0 % 23.75 [ 7.12, 40.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Highly restricted, organic diet
Bartel 2008 5 196 (20) 9 192 (20) 100.0 % 4.00 [ -17.86, 25.86 ]
Subtotal (95% CI) 5 9 100.0 % 4.00 [ -17.86, 25.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 1.99, df = 1 (P = 0.16), I2 =50%
-100 -50 0 50 100
Favours control diet Favours intervention diet
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Analysis 1.6. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 6 Need
for surgery.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 6 Need for surgery
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low microparticle diet
Lomer 2001 1/10 0/10 100.0 % 3.00 [ 0.14, 65.90 ]
Subtotal (95% CI) 10 10 100.0 % 3.00 [ 0.14, 65.90 ]
Total events: 1 (Intervention diet), 0 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
2 Low fiber diet
Levenstein 1985 5/30 4/28 100.0 % 1.17 [ 0.35, 3.91 ]
Subtotal (95% CI) 30 28 100.0 % 1.17 [ 0.35, 3.91 ]
Total events: 5 (Intervention diet), 4 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 1.7. Comparison 1 Intervention diet versus control diet in active Crohn’s disease, Outcome 7
Disease progression.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 1 Intervention diet versus control diet in active Crohn’s disease
Outcome: 7 Disease progression
Study or subgroup Experimental diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Highly restricted, organic diet
Bartel 2008 1/5 3/9 100.0 % 0.60 [ 0.08, 4.35 ]
Subtotal (95% CI) 5 9 100.0 % 0.60 [ 0.08, 4.35 ]
Total events: 1 (Experimental diet), 3 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Low fiber diet
Levenstein 1985 11/30 8/28 100.0 % 1.28 [ 0.61, 2.72 ]
Subtotal (95% CI) 30 28 100.0 % 1.28 [ 0.61, 2.72 ]
Total events: 11 (Experimental diet), 8 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 2.1. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 1
Clinical relapse.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 1 Clinical relapse
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low refined carbohydrate diet
Brandes 1981 1/5 1/6 0.5 % 1.20 [ 0.10, 14.69 ]
Lorenz-Meyer 1996 45/69 96/135 44.1 % 0.92 [ 0.75, 1.12 ]
Ritchie 1987 130/190 96/162 55.4 % 1.15 [ 0.98, 1.36 ]
Subtotal (95% CI) 264 303 100.0 % 1.04 [ 0.87, 1.25 ]
Total events: 176 (Intervention diet), 193 (Control diet)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.06, df = 2 (P = 0.22); I2 =35%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Symptoms-guided diet
Jones 1985 3/10 10/10 32.9 % 0.33 [ 0.14, 0.80 ]
Riordan 1993 21/40 30/38 67.1 % 0.67 [ 0.47, 0.93 ]
Subtotal (95% CI) 50 48 100.0 % 0.53 [ 0.28, 1.01 ]
Total events: 24 (Intervention diet), 40 (Control diet)
Heterogeneity: Tau2 = 0.13; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.92 (P = 0.055)
3 Low red, processed meat diet
Albenberg 2018 63/96 75/118 100.0 % 1.03 [ 0.85, 1.26 ]
Subtotal (95% CI) 96 118 100.0 % 1.03 [ 0.85, 1.26 ]
Total events: 63 (Intervention diet), 75 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
4 Exclusion diets (low disaccharides, grains, saturated fats, red and processed meats)
Mutlu 2016 0/16 10/38 100.0 % 0.11 [ 0.01, 1.76 ]
Subtotal (95% CI) 16 38 100.0 % 0.11 [ 0.01, 1.76 ]
Total events: 0 (Intervention diet), 10 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 6.42, df = 3 (P = 0.09), I2 =53%
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 2.2. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 2
Surrogate inflammatory biomarker - CRP.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 2 Surrogate inflammatory biomarker - CRP
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Symptoms-guided diet
Riordan 1993 40 2.71 (6.58) 38 2.42 (2.9) 0.29 [ -1.95, 2.53 ]
-100 -50 0 50 100
Favours intervention diet Favours control diet
Analysis 2.3. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 3
Surrogate inflammatory biomarker - ESR.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 3 Surrogate inflammatory biomarker - ESR
Study or subgroup
Favours
intervention
diet Control diet
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Symptoms-guided diet
Jones 1985 7 16.2 (12.5) 10 30.8 (25.7) 29.0 % -14.60 [ -33.02, 3.82 ]
Riordan 1993 40 29.6 (25.9307) 38 33.9 (27.1234) 71.0 % -4.30 [ -16.09, 7.49 ]
Total (95% CI) 47 48 100.0 % -7.29 [ -17.22, 2.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours intervention diet Favours control diet
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Analysis 2.4. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 4
Need for surgery.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 4 Need for surgery
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low refined carbohydrate diet
Brandes 1981 1/10 1/10 9.9 % 1.00 [ 0.07, 13.87 ]
Ritchie 1987 7/190 15/162 90.1 % 0.40 [ 0.17, 0.95 ]
Total (95% CI) 200 172 100.0 % 0.44 [ 0.19, 1.00 ]
Total events: 8 (Intervention diet), 16 (Control diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
Analysis 2.5. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 5
Disease progression.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 5 Disease progression
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low refined carbohydrate diet
Brandes 1981 1/5 1/6 1.20 [ 0.10, 14.69 ]
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 2.6. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 6
Escalation of therapy.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 6 Escalation of therapy
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low refined carbohydrate diet
Brandes 1981 1/10 0/10 3.00 [ 0.14, 65.90 ]
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
Analysis 2.7. Comparison 2 Intervention diet versus control diet in inactive Crohn’s disease, Outcome 7
Withdrawals due to adverse events.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 2 Intervention diet versus control diet in inactive Crohn’s disease
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptoms-guided diet
Riordan 1993 0/40 2/38 0.19 [ 0.01, 3.84 ]
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 3.1. Comparison 3 Intervention diet versus control diet in active ulcerative colitis, Outcome 1
Induction of remission.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 3 Intervention diet versus control diet in active ulcerative colitis
Outcome: 1 Induction of remission
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptoms-guided diet
Candy 1995 4/11 0/10 100.0 % 8.25 [ 0.50, 136.33 ]
Subtotal (95% CI) 11 10 100.0 % 8.25 [ 0.50, 136.33 ]
Total events: 4 (Intervention diet), 0 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control diet Favours intervention diet
Analysis 3.2. Comparison 3 Intervention diet versus control diet in active ulcerative colitis, Outcome 2
Clinical improvement.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 3 Intervention diet versus control diet in active ulcerative colitis
Outcome: 2 Clinical improvement
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptoms-guided diet
Candy 1995 5/11 1/10 4.55 [ 0.63, 32.56 ]
0.01 0.1 1 10 100
Favours control diet Favours intervention diet
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Analysis 3.3. Comparison 3 Intervention diet versus control diet in active ulcerative colitis, Outcome 3
Endoscopic improvement.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 3 Intervention diet versus control diet in active ulcerative colitis
Outcome: 3 Endoscopic improvement
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptoms-guided diet
Candy 1995 8/11 2/10 3.64 [ 1.00, 13.23 ]
0.01 0.1 1 10 100
Favours control diet Favours intervention diet
Analysis 3.4. Comparison 3 Intervention diet versus control diet in active ulcerative colitis, Outcome 4
Histologic improvement.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 3 Intervention diet versus control diet in active ulcerative colitis
Outcome: 4 Histologic improvement
Study or subgroup Intervention diet Control diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptoms-guided diet
Candy 1995 3/11 3/10 0.91 [ 0.24, 3.51 ]
0.01 0.1 1 10 100
Favours control diet Favours intervention diet
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Analysis 4.1. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 1
Clinical relapse.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 1 Clinical relapse
Study or subgroup Intervention diet Control diet Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anti-inflammatory diet (Alberta-based)
Keshteli 2016 5/14 4/14 100.0 % 1.25 [ 0.42, 3.70 ]
Subtotal (95% CI) 14 14 100.0 % 1.25 [ 0.42, 3.70 ]
Total events: 5 (Intervention diet), 4 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Carrageenan-free diet
Bhattacharyya 2017 3/10 3/5 100.0 % 0.50 [ 0.15, 1.64 ]
Subtotal (95% CI) 10 5 100.0 % 0.50 [ 0.15, 1.64 ]
Total events: 3 (Intervention diet), 3 (Control diet)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
3 Milk free diet
Strisciuglio 2013 7/13 8/15 22.5 % 1.01 [ 0.51, 2.01 ]
Wright 1965 16/26 18/23 77.5 % 0.79 [ 0.54, 1.14 ]
Subtotal (95% CI) 39 38 100.0 % 0.83 [ 0.60, 1.15 ]
Total events: 23 (Intervention diet), 26 (Control diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
0.01 0.1 1 10 100
Favours intervention diet Favours control diet
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Analysis 4.2. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 2
Fecal calprotectin.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 2 Fecal calprotectin
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Carrageenan-free diet
Bhattacharyya 2017 10 171 (143) 5 111 (91) 60.00 [ -59.24, 179.24 ]
-100 -50 0 50 100
Favours intervention diet Favours control diet
Analysis 4.3. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 3
Surrogate inflammatory biomarker - TNF-α.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 3 Surrogate inflammatory biomarker - TNF-
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carrageenan-free diet
Bhattacharyya 2017 5 6.3 (4.9) 7 10.8 (1.4) -4.50 [ -8.92, -0.08 ]
-10 -5 0 5 10
Favours intervention diet Favours control diet
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Analysis 4.4. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 4
Surrogate inflammatory biomarker - IL-6.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 4 Surrogate inflammatory biomarker - IL-6
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carrageenan-free diet
Bhattacharyya 2017 5 5 (2.31) 7 3.06 (1.44) 1.94 [ -0.35, 4.23 ]
-10 -5 0 5 10
Favours intervention diet Favours control diet
Analysis 4.5. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 5
Surrogate inflammatory biomarker - IL-8.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 5 Surrogate inflammatory biomarker - IL-8
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carrageenan-free diet
Bhattacharyya 2017 5 207 (180) 7 169 (109) 38.00 [ -139.24, 215.24 ]
-100 -50 0 50 100
Favours intervention diet Favours control diet
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Analysis 4.6. Comparison 4 Intervention diet versus control diet in inactive ulcerative colitis, Outcome 6
Health related quality of life - SIBDQ.
Review: Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
Comparison: 4 Intervention diet versus control diet in inactive ulcerative colitis
Outcome: 6 Health related quality of life - SIBDQ
Study or subgroup Intervention diet Control diet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carrageenan-free diet
Bhattacharyya 2017 7 63.3 (4.3) 5 61.6 (6.5) 1.70 [ -4.83, 8.23 ]
-10 -5 0 5 10
Favours control diet Favours intervention diet
A D D I T I O N A L T A B L E S
Table 1. Dietary components can influence risk of inflammatory bowel disease
Dietary Component Effect on IBD Risk References
Animal Protein Increased Jantchou 2010
Heme iron, sulfur Increased Ananthakrishnan 2015
Refined sugars Increased Janerot 1983
High trans-fat Increased Ananthakrishnan 2014
Fiber Decreased Ananthakrishnan 2015
Fruit Decreased Hou 2011
Vegetables Decreased Hou 2011
High omega-3 fatty acids Decreased Chan 2014
Adpated from Mullin 2016.
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Table 2. Summary of interventions and outcomes
Study ID Group 1 (n) Group 2 (n) Group 3 (n) Group 4 (n) Remission Relapse
Induction of Remission in Crohn’s Disease
Bartel 2008 Restricted
organic diet (5)
Low-fat, high-
carbohydrate,
low-fiber, no red
meat diet (9)
4/5 vs. 7/9 (week
6)
PP:4/5 vs. 5/9
(week 24)
ITT: 4/8 vs. 5/10
N/A
Brotherton 2014 High-
fiber, reduced re-
fined carbohy-
drate diet (4)
Low-fiber diet
(3)
Remission: 4/4
vs. 0/3 (week 4)
Change in
pHBI: 5.8 to 0.5
vs. 5.2 to 3.5 (P
= 0.008)
N/A
Dariel 2007 Sequential elim-
ination diets for
30 food compo-
nents (32)
Conventional
nutritional
advice (19)
Response: 16/32
vs. 1/19
Remission: 16/
32 vs. 0/19
N/A
Levenstein 1985 Low fiber diet Normal
diet (with grad-
ual fiber intro-
duction)
Not reported N/A
Lomer 2001 Diet low in mi-
croparticles. Fi-
brous fruit and
vegetables were
excluded (10)
Foods contain-
ing dietary mi-
croparticles were
not discouraged.
Fibrous fruit and
vegetables were
excluded (10)
PP: 7/9 vs. 0/9
(month 4)
ITT: 7/10 vs. 0/
10
N/A
Lomer 2005 Low calcium and
low microparti-
cle diet (22)
Low
calcium and nor-
mal microparti-
cle diet (21)
Nor-
mal calcium and
low microparti-
cle diet (20)
Normal calcium
and normal mi-
croparticle diet
(20)
Low vs. normal
microparticle
groups.
Response: 16/42
vs. 17/41 (week
16)
Remission:
16/42 vs. 13/41
(week 16)
Low versus nor-
mal calcium
Remission:
16/43 versus 13/
40
N/A
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Table 2. Summary of interventions and outcomes (Continued)
Maintenance of Remission in Crohn’s Disease
Albenberg 2018 Low red and pro-
cessed meats
(96)
Moderate red
and processed
meats (118)
N/A 54/87 vs. 72/115
(week 48)
Brandes 1981 Low carbo-
hydrate diet with
increased intake
of protein and fat
High carbo-
hydrate diet with
reduced intake of
protein and fat
N/A 1/5 vs. 1/6
Jones 1985 Exclusion
of foods that pro-
voked symptoms
(10)
Unrefined car-
bohydrate fiber-
rich diet (10)
N/A 3/10 vs. 10/10
(month 6)
Lorenz-Meyer
1996
Low-car-
bohydrate diet of
less than 84 g/
day (69)
Omega-3 fatty
acid capsules and
general nutrition
guidelines (70)
Placebo and
general nutrition
guidelines (65)
N/A 45/69 vs. 50/70
vs. 46/65
Mutlu 2016 Anti-IBD
diet and placebo
supplement (16)
Fructooligosac-
cha-
ride supplement
and “placebo
diet” (19)
“Placebo diet”
and placebo sup-
plement (19)
N/A 0/16 vs. 6/19 vs.
4/19 (month 12)
Riordan 1993 El-
emental diet fol-
lowed by reintro-
duction of sin-
gle food each day
and exclusion of
symptom-
provoking foods
(40)
General di-
etary advice and
prednisolone ta-
per (38)
N/A PP: 12/40 vs. 25/
38 (month 24)
ITT: 21/40 vs.
30/38
Ritchie 1987 Unrefined, fiber-
rich diet (190)
Refined carbo-
hydrate-rich diet
and unre-
stricted sugar in-
take (162)
N/A 130/190 vs. 96/
162 (month 24)
Induction of Remission in Ulcerative Colitis
Candy 1995 Systematic ex-
clusion of symp-
toms-provoking
foods (11)
Usual diet (10) Response: 9/11
vs. 1/7 (week 6)
Remission: 4/11
vs. 0/7 (week 6)
N/A
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Table 2. Summary of interventions and outcomes (Continued)
Maintenance of Remission in Ulcerative Colitis
Bhattacharyya
2017
Carrageenan-
free diet +
placebo (10)
Carrageenan-
free diet + car-
rageenan-con-
taining capsules
(5)
N/A PP: 0/7 vs. 3/5
(month 12)
ITT: 3/10 vs. 3/
5
Keshteli 2016 Alberta-based
Anti-inflamma-
tory Diet (14)
Diet based on
Canada’s Food
Guide (14)
N/A 5/14 vs. 4/14
(month 6)
Strisciuglio 2013 Cow’s milk pro-
tein elimination
diet (14)
Usual diet (15) N/A 5/13 vs. 4/15
(month 6)
7/13 vs. 8/15
(month 12)
Wright 1965 Milk-free, low-
roughage diet
(26)
Exclusion
diet and liberal
consumption of
milk and milk
products (24)
N/A 16/26 vs. 18/23
(month 12)
Abbreviations: ITT, Intention-to-treat; N/A, not applicable; pHBI, partial Harvey-Bradshaw Index; PP, per-protocol
A P P E N D I C E S
Appendix 1. Medline Search Strategy
MEDLINE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
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15. Exp Inflammatory bowel disease/
16. Crohn*.tw.
17. Ulcerative colitis.tw.
18. IBD.tw.
19. Inflammatory bowel disease.tw.
20. Regional ileitis.tw.
21. Colitis.tw.
22. or/15-21
23. Exp Diet/
24. Diet therapy.tw.
25. Diet*.tw.
26. Regimen.tw.
27. Nutrition*.tw.
28. Elimination.tw.
29. Eliminat*.tw.
30. (food* OR oligosaccharides OR oligofructose OR fructooligosaccharide* OR monosaccharide*). tw.
31. (maker* diet OR fodmap* OR gluten* OR polyols OR omega* OR sugar* OR carbo* OR fruit* OR vegetable* OR sodium OR
fatty acid* OR dairy OR fiber OR fibre OR protein*).tw.
32. (Vegetarian OR veganORmacro* OR keto* ORpaleoORdissacharide* OR lactose OR sucrose OR fructose OR bran* OR solbitol
OR xylitol OR psyllium ORMetamucil OR plantaglucide OR ispaghula OR isogel OR reguval OR plantago seed OR ispaghule gum
).tw.
33. Or/23-32
35. 14 and 22 and 33
Embase
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross over$ or cross-over$).mp.
4. placebo$.mp.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
10. (tripl$ adj blind$).mp.
11. assign$.mp.
12. allocat$.mp.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. Exp Inflammatory bowel disease/
20. Crohn*.tw.
21. Ulcerative colitis.tw.
22. IBD.tw.
23. Inflammatory bowel disease.tw.
24. Regional ileitis.tw.
25. Colitis.tw.
26. or/19-25
27. Exp Diet/
28. Diet therapy.tw.
29. Diet*.tw.
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30. Regimen.tw.
31. Nutrition*.tw.
32. Elimination.tw.
33. Eliminat*.tw.
34. (Food* OR oligosaccharides OR oligofructose OR fructooligosaccharide* OR monosaccharide*). tw.
35. (maker* diet OR fodmap* OR gluten* OR polyols OR omega* OR sugar* OR carbo* OR fruit* OR vegetable* OR sodium OR
fatty acid* OR dairy OR fiber OR fibre OR protein*).tw.
36. (Vegetarian OR veganORmacro* OR keto* ORpaleoORdissacharide* OR lactose OR sucrose OR fructose OR bran* OR solbitol
OR xylitol OR psyllium ORMetamucil OR plantaglucide OR ispaghula OR isogel OR reguval OR plantago seed OR ispaghule gum
).tw.
37. Or/27-36
39. 18 and 26 and 37
CENTRAL
#1 MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees
#2 crohn* or IBD or (inflammatory bowel disease*) or (ulcerative colitis) or colitis
#3 #1 or #2
#4 MeSH descriptor: [Diet] explode all trees
#5 Diet therapy
#6 Diet*
#7 Regimen
#8 Nutrition*
#9 Elimination
#11 Food* OR oligosaccharides OR oligofructose OR fructooligosaccharide* OR monosaccharide*
#12 Maker* diet OR fodmap* OR gluten* OR polyols OR omega* OR sugar* OR carbo* OR fruit* OR vegetable* OR sodium OR
fatty acid* OR dairy OR fiber OR fibre OR protein*
#13 Vegetarian OR vegan ORmacro*OR keto* OR paleoORdissacharide* OR lactose OR sucrose OR fructose OR bran* OR solbitol
OR xylitol OR psyllium ORMetamucil OR plantaglucide OR ispaghula OR isogel OR reguval OR plantago seed OR ispaghule gum
#14 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#20 #3 and #14
Web of Science
#1 TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=
follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
#2 TS= (“inflammatory bowel disease” OR “inflammatory bowel diseases” OR “ibd” OR “crohn” OR “crohns” OR “terminal ileitis”
OR “enteritis regionalis” OR “Regional enteritis” OR “regional enterocolitis” OR “Ileitis” OR “colitis” OR proctit* OR proctocolit*
OR colitide* OR “ulcerative colorectitis”)
#3 TS=(diet OR “diets” OR “dietary” OR “oligosaccharides” OR “oligofructose” OR “raw food” OR fermented OR “Whole 30” OR
“atkins” OR “south beach” OR “makers diet” OR “maker’s diet” OR fodmap OR fodmaps OR fructooligosaccharide* OR polyols OR
monosaccharide* OR gluten OR “fish diet” OR “fatty acid” OR “fatty acids” OR omega-3 OR omega-3s OR omega-6 OR omega-6s
OR elimination ORmicroparticle OR “red meat” OR sugar OR sugars OR dairy OR fiber OR fibre OR low-residue OR “low residue”
OR fruit OR fruits OR vegetable OR vegetables OR “olive oil” OR “olive oils” OR “Protein diet” OR “protein diets” OR “Protein
restricted” OR “Protein-restricted” OR “Protein-free” OR “Protein free” OR carbohydrate OR carbo OR “fad diet” OR “fad diets”
OR “high fat” OR “high fats” ORMediterranean OR Paleolithic OR paleo OR sodium OR vegetarian OR vegan ORmacrobiotic OR
ketogenic OR “antinflammatory diet” OR “anti-inflammatory diet” OR “IBD AID” OR “IBD-AID” OR dissacharide* OR lactose
OR sucrose OR fructose OR “exclusion diet” OR “exclusion diets” OR SCDOR solbitol OR xylitol OR bran OR brans OR psyllium
OR Metamucil OR plantaglucide OR “ispaghule gum” OR “plantago seed” OR ispaghula OR isogel OR reguval)
#4 #1 AND #2 AND #3
Clinical trials. Gov
1. Diet and Inflammatory bowel disease
2. Diet and Ulcerative colitis
3. Diet and Crohn’s Disease
IBD Group Specialized Register
1. Diet and Inflammatory bowel disease
2. Diet and Ulcerative colitis
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3. Diet and Crohn’s Disease
WHO trial registry (ICTRP)
1. Diet and Inflammatory bowel disease
2. Diet and Ulcerative colitis
3. Diet and Crohn’s Disease
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following successful publication of the protocol, support from the UK authors who were funded by an NIHR Cochrane Programme
grant was added. One element of the protocol that was revisited was the consideration of including non-randomized trials. This was
an initial decision based on the perception that few studies would be discovered. However, within the very early phases of considering
citations, it was clear this was not the case and a discussion between the team was held and the advice of the editorial base sought. It was
decided to amend and only include randomized trials. In the protocol, we planned to calculate odds ratios for dichotomous outcomes
as this effect measure is often more appropriate when including observational data. Once we decided to only include randomized trials,
we decided that the risk ratio would be more appropriate effect measure to use. In the protocol we did not specify how we would deal
with multi-arm trials. For studies with multiple treatment arms, we only included single pair-wise comparisons as appropriate.
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